Image-guided therapy of a tissue

Description

BACKGROUND

Cancerous brain tumors can be “primary” tumors, meaning that the tumors originate in the brain. Primary tumors include brain tissue with mutated DNA that grows (sometimes aggressively) and displaces or replaces healthy brain tissue. Gliomas are one type of primary tumor that indicate cancer of the glial cells of the brain. While primary tumors can appear as single masses, they can often be quite large, irregularly-shaped, multi-lobed and/or infiltrated into surrounding brain tissue.

Primary tumors may not be diagnosed until the patient experiences symptoms, including those such as headaches, altered behavior, and sensory impairment. However, by the time the symptoms develop, the tumor may already be large and aggressive.

One treatment for cancerous brain tumors is surgery. Surgery involves a craniotomy (i.e., removal of a portion of the skull), dissection, and total or partial tumor resection. The objectives of surgery may include removing or lessening of the number of active malignant cells within the brain, or reducing a patient's pain or functional impairment due to the effect of the tumor on adjacent brain structures. Not only can surgery be invasive and accompanied by risks, for some tumors, surgery is often only partially effective. In other tumors, surgery may not be feasible. Surgery may risk impairment to the patient, may not be well-tolerated by the patient, and/or may involve significant costs, recovery time, and recovery efforts.

Another treatment for cancerous brain tumors is stereotactic radiosurgery (SRS). SRS is a treatment method by which multiple intersecting beams of radiation are directed at the tumor such that, at the point of intersection of the beams, a lethal dose of radiation is delivered, while tissue in the path of any single beam remains unharmed. However, confirmation that the tumor has been killed is often not possible for several months post-treatment. Furthermore, in situations where high doses of radiation may be required to kill a tumor, such as in the case of multiple or recurring tumors, it is common for the patient to reach a toxic threshold for radiation dose, prior to killing all of the tumors. Reaching this toxic threshold renders further radiation is inadvisable.

SUMMARY

A system or method for effecting treatment to a tissue, in some implementations, includes an automated drive mechanism with a holder to hold a treatment device (e.g., medical probe, ultrasonic applicator, laser fiber, etc.). In some implementations, the drive mechanism is motorless and consists of thermal imaging compatible components. The drive mechanism, for example, can be configured without an electric motor. The drive mechanism, in some examples, is included in an MRI or MRI head coil. The drive mechanism can be coupled to one or more wires or umbilicals such that a translation of the one or more wires or umbilicals affects one or more of a longitudinal displacement of the holder and a rotation of the holder. A controller, in some implementations, processes position control signals for setting and/or monitoring a position of the holder (e.g., via an input interface to the wires or umbilicals), and issues subsequent position control signals to manipulate positioning of the holder (e.g., via an output interface to the wires or umbilicals).

The system or method, in some implementations, includes a guide mechanism that is attachable to a surface of a patient. The guide mechanism, for example, can include a base structure configured to remain stationary relative to the patient when the guide mechanism is attached to the surface of the patient in a locked state. The guide mechanism can further include a tilt portion that is coupled to the base structure and provides an adjustable tilt between a trajectory of the drive mechanism and the base structure. The guide mechanism can further include a rotation portion that provides an adjustable rotation of the tilt portion relative to the base structure.

The controller, in some implementations, is configured to process a sequence of the position control signals to direct the guide mechanism to move the holder during treatment. For example, the controller can be programmed to move the holder to a first position for effecting the treatment to the tissue at a first portion of the tissue that coincides with the first position and then move the holder to a second position for effecting the treatment to the tissue at a second portion of the tissue that coincides with the second position.

During treatment, in some implementations, a workstation transmits the position control signals to the controller and displays feedback images (e.g., MRI images and/or thermometry images) of the tissue to an operator of the workstation. The workstation, for example, can continuously display the thermometry images of the tissue during the treatment to the tissue at the first and second portions of the tissue, and while the holder moves between the first and second positions.

In some implementations, an imaging system receives images of the tissue and the treatment device and analyzes the images to monitor control of positioning and/or therapeutic energy delivery within the tissue. For example, the imaging system may process, in real time, the images of the tissue and the treatment device and the thermometry images of the tissue to forecast errors or interruptions in the treatment to the tissue. Responsive to the analysis, the imaging system may display, via the workstation, a corresponding warning. Position control signals may be updated and transmitted by the workstation to the controller based on one or more of the images, as the images are received by the workstation in real time.

In some implementations, treatment is delivered via an energy emission probe, such as an ultrasonic applicator or laser probe. The energy emission probe, in some examples, may include one or more emitters, such as a radiofrequency emitter, a high-intensity focused ultrasound emitter, a microwave emitter, a cryogenic cooling device, and a photodynamic therapy light emitter. The energy emission probe may include multiple emitters, where the emitters are longitudinally spaced with respect to a longitudinal axis of the energy emission probe.

In some implementations, the energy emission of the probe can be controlled to generate a number of different output patterns. The different patterns, for example, can include energy delivered via two or more ultrasonic transducers and/or two or more laser fibers. For example, a laser probe may include a first laser fiber for outputting a symmetrical output pattern with respect to a longitudinal axis of the first laser fiber and a second laser fiber for outputting an asymmetrical output pattern with respect to a longitudinal axis of the second laser fiber. In another example, an ultrasonic applicator may include a first ultrasonic transducer for outputting a first ultrasonic frequency and a second ultrasonic transducer for outputting a second ultrasonic frequency.

The output pattern, in some implementations, includes a pulsed output pattern. For example, a higher power density may be achieved without causing tissue scorching by pulsing a high power laser treatment for x seconds with y seconds break between (e.g., for tissue in the immediate vicinity to cool down). In a particular example, the laser pattern may be active for two seconds and inactive for one second.

In some implementations, the treatment pattern includes effecting treatment while simultaneously moving the probe (e.g., linearly and/or rotationally). For example, an ultrasonic probe may be rotated while an emission pattern is simultaneously adjusted to effect treatment to a desired depth based upon a particular geometry of the region of interest (ROI). In this manner, for example, while the ultrasonic treatment beam is focused upon a radial portion of the tumor having a depth of 1.5 centimeters, the power density of the HIFU probe may be tuned for the first treatment depth. Upon rotation, a second radial portion of the tumor may have a depth of 2 centimeters, and the power density of the HIFU probe may be increased accordingly to tune for the treatment depth of 2 centimeters.

An energy source may be included to generate energy for the probe. In some implementations, the workstation transmits energy control signals to the energy source. The workstation, for example, may be configured to process a sequence of the energy control signals to first effect a symmetrical treatment to the tissue with the probe and then effect an asymmetrical treatment to the tissue with the probe after the symmetrical treatment. In a particular example, the workstation may be configured to process a sequence of position and laser control signals to move the holder to a first position for effecting the treatment to the tissue at a first portion of the tissue that coincides with the first position, effect a symmetrical treatment to the first portion of the tissue with the first laser fiber, move the holder to a second position for effecting the treatment to the tissue at a second portion of the tissue that coincides with the second position, and effect an asymmetrical treatment to the second portion of the tissue with the second laser fiber. During treatment, the workstation may be configured to display thermometry images of the tissue continuously throughout processing of the sequence of the position and energy control signals while effecting the symmetrical and asymmetrical treatments.

In some implementations, the system or method includes a guide sheath configured to accept two or more probes of different modalities as the treatment device. The modalities may include, for example, laser, radiofrequency, high-intensity focused ultrasound, microwave, cryogenic, photodynamic therapy, chemical release and drug release. The guide sheath may include one or more off-axis lumens (holes) for positioning an emitting point of one or more of the number of probes at an off-axis angle.

The system or method may include one or more processors and circuits that embody aspects of various functions by executing corresponding code, instructions and/or software stored on tangible memories or other storage products. A display may include various flat-panel displays, including liquid crystal displays.

In one aspect, the present disclosure relates to an apparatus including a low profile skull anchor device configured to attach to an area of a skull of a patient, the low profile skull anchor device including a central opening for access to an entry formed in the skull of the patient, where the low profile skull anchor device, upon attachment to the area of the skull, protrudes from the area of the skull at a height no greater than forty millimeters. The apparatus may further include a removable guide stem configured to detachably connect to the low profile skull anchor device, the removable guide stem including a cylindrical opening, where upon connection of the removable guide stem to the low profile skull anchor device, the cylindrical opening is positioned substantially above the entry formed in the skull of the patient, and the removable guide stem is configured to adjust a trajectory of the cylindrical opening in at least one of a tilt direction and a rotation direction.

In some implementations, the low profile skull anchor device includes at least three fastener positions for attaching the low profile skull anchor device to bone anchors set in the skull of the patient using screws. The low profile skull anchor device may include at least three skull pins for maintaining a gap between the low profile skull anchor device and a surface of the skull of the patient, thereby avoiding skin compression. The central opening of the low profile skull anchor device may be at least sixty millimeters in diameter.

In some implementations, the low profile skull anchor device includes at least two fastener openings for connecting the removable guide stem to the low profile skull anchor device. The removable guide stem may include a ball joint for adjusting the trajectory of the cylindrical opening in both the tilt direction and the rotation direction. The removable guide stem may include a tilt adjustment mechanism for adjusting the trajectory of the cylindrical opening in a tilt direction and a separate rotation adjustment mechanism for adjusting the trajectory of the cylindrical opening in a rotation direction. At least one of the removable guide stem and the low profile skull anchor device may include a number of guide lines for aid in setting the trajectory of the cylindrical opening.

In some implementations, the apparatus includes a guide sheath, where the guide sheath is configured for insertion within the cylindrical opening of the removable guide stem, and the guide sheath includes at least one hollow lumen extending between a proximal end of the guide sheath and a distal end of the guide sheath, where the at least one hollow lumen is configured for introduction of a neurosurgical instrument. The removable guide stem may include a lock mechanism for locking the guide sheath to the removable guide stem at a selected linear depth of insertion within the cylindrical opening of a number of linear depths of insertion available for selection. The distal end of the guide sheath may include two or more openings for deployment of the neurosurgical instrument.

In one aspect, the present disclosure relates to a head fixation system including an upper ring portion including a nose indent for positioning the nose of a patient when a head of the patient is encircled by the head fixation system, and a lower ring portion including a number of support posts, where the number of support posts are configured to support the head of the patient laid upon the lower ring portion, and the lower ring portion is configured to lock to the upper ring portion after positioning the head of the patient upon the number of support posts.

In some implementations, the support posts are adjustably connected to the lower ring portion via a number of slots, where the head fixation system includes more slots than support posts. Each support post of the number of support posts may include at least one connection point for connecting a fastener. The at least one connection point may be configured for connection of a skull pin. Each support post of the number of support posts may include at least three connection points for connecting a fastener, where a positioning of a fastener upon a first support post of the number of support posts is user selectable. Upon positioning the head of the patient between the lower ring portion and the upper ring portion and locking the lower ring portion to the upper ring portion, a user may tighten the fasteners to fix a position of the head of the patient.

In some implementations, the head fixation system includes one or more additional upper ring portions, where the upper ring portion is selected based upon a size of the head of the patient. The lower ring portion may be curved to provide at least forty degrees of angular head adjustment upon placing the head fixation system within a fixation ring channel of a patient table.

In one aspect, the present disclosure relates to a probe for use in effecting intracranial high intensity focused ultrasound (HIFU) treatment, including at least one ultrasonic transducer, an acoustic coupling medium contacting the at least one ultrasonic transducer, and a rigid external shaft for interstitial positioning of the at least one ultrasonic transducer, where the rigid shaft is up to 3.5 millimeters in diameter, and the at least one ultrasonic transducer is mounted within the rigid external shaft. The probe may be configured to drive ultrasonic energy at least three centimeters into tissue for effecting thermal treatment of the tissue.

In some implementations, the at least one ultrasonic transducer is mounted in a side-firing position within the rigid external shaft. The at least one ultrasonic transducer may include a linear array of three or more ultrasonic transducers. The at least one ultrasonic transducer may be a planar transducer. The thermal treatment may include one of coagulation and cavitation.

The foregoing general description of the illustrative implementations and the following detailed description thereof are merely example aspects of the teachings of this disclosure, and are not restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of an exemplary layout of an MRI Control Room, an MRI Scan Room, and an MRI Equipment Room;

FIG. 2 is an illustration of a perspective view of a patient inserted into an MRI, with a head fixation and stabilization system installed;

FIG. 3 illustrates a probe driver;

FIGS. 4A and 4B are flow charts illustrating an exemplary procedure for treating a patient;

FIGS. 5A through 5E illustrate a low profile skull anchoring device and exemplary guide stems;

FIGS. 5F and 5G illustrate a guide stem and sheath configured to interconnect with the low profile skull anchoring device;

FIGS. 5H and 5I illustrate example internal configurations of a guide sheath;

FIG. 6 is a flow chart illustrating an example method for determining trajectory adjustments based upon initial position and orientation of probe introduction equipment upon the skull of a patient;

FIGS. 7A through 7C illustrate a high intensity focused ultrasound probe;

FIGS. 8A and 8B illustrate a method for MR thermal monitoring using offset thermal imaging planes; and

FIG. 9 illustrates exemplary hardware of a workstation.

DETAILED DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENTS

In the drawings, like reference numerals designate identical or corresponding parts throughout the several views.

As used herein, the words “a,” “an” and the like generally carry a meaning of “one or more,” unless stated otherwise. The term “plurality”, as used herein, is defined as two or more than two. The term “another”, as used herein, is defined as at least a second or more. The terms “including” and/or “having”, as used herein, are defined as comprising (i.e., open language). The term “program” or “computer program” or similar terms, as used herein, is defined as a sequence of instructions designed for execution on a computer system. A “program”, or “computer program”, may include a subroutine, a program module, a script, a function, a procedure, an object method, an object implementation, in an executable application, an applet, a servlet, a source code, an object code, a shared library/dynamic load library and/or other sequence of instructions designed for execution on a computer system.

Reference throughout this document to “one embodiment”, “certain embodiments”, “an embodiment”, “an implementation”, “an example” or similar terms means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present disclosure. Thus, the appearances of such phrases or in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more examples without limitation.

The term “or” as used herein is to be interpreted as an inclusive or meaning any one or any combination. Therefore, “A, B or C” means “any of the following: A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.

Further, in individual drawings figures, some components/features shown are drawn to scale to exemplify a particular implementation. For some drawings, components/features are drawn to scale across separate drawing figures. However, for other drawings, components/features are shown magnified with respect to one or more other drawings. Measurements and ranges described herein relate to example embodiments and identify a value or values within a range of 1%, 2%, 3%, 4%, 5%, or, preferably, 1.5% of the specified value(s) in various implementations.

The treatment of tumors by heat is referred to as hyperthermia or thermal therapy. Above approximately 57° C., heat energy needs only to be applied for a short period of time since living tissue is almost immediately and irreparably damaged and killed, for example through a process called coagulation, necrosis, or ablation. Malignant tumors, because of their high vascularization and altered DNA, are more susceptible to heat-induced damage than healthy tissue. In other procedures, heat energy is applied to produce reversible cell damage. Temporary damage to cellular structures may cause the cells to be more conducive to certain therapies including, in some examples, radiation therapy and chemotherapy. Different types of energy sources, for example, laser, microwave, radiofrequency, electric, and ultrasound sources may be selected for heat treatment based on factors including: the type of tissue that is being treated, the region of the body in which the tissue to be treated is located, whether cellular death or reversible cellular damage is desired, the nature of energy application parameters for each source, and variability of the energy application parameters. Depending on these factors, the energy source may be extracorporeal (i.e., outside the body), extrastitial (i.e., outside the tumor), or interstitial (i.e., inside the tumor).

In interstitial thermal therapy (ITT), a tumor is heated and destroyed from within the tumor itself, energy may be applied directly to the tumor instead of requiring an indirect route through surrounding healthy tissue. In ITT, energy deposition can be extended throughout the entire tumor. The energy can be applied to heat tissue in the treatment area to a temperature within a range of about 45° to 60° C.

An exemplary ITT process begins by inserting an ultrasound applicator including one or more transducers into the tumor. The ultrasonic energy from the applicator may therefore extend into the tissue surrounding the end or tip including the one or more transducers to effect heating within the tumor. In some implementations, the transducer(s) is/are aligned with an edge of the applicator and the applicator is rotatable so as to rotate the ultrasonic energy beam around the axis of the applicator to effect heating of different parts of the tumor at positions around the applicator. In other implementations or for other applications, the transducer(s) are presented on a tip of the applicator or otherwise surrounding an inserted portion of the applicator. Depending upon the distribution of transducers, the applicator may be moved longitudinally and/or rotated to effect heating of the tumor over a full volume of the targeted region.

In yet other implementations, the ultrasonic applicator is controlled and manipulated by a surgeon with little or no guidance apart from the surgeon's memory of the anatomy of the patient and the location of the tumor. In still other implementations, images may be used during the ITT process to provide guidance for treatment. For example, locations of tumors and other lesions to be excised can be determined using a magnetic resonance imaging (MRI) system or computer tomography (CT) imaging system. During the ITT process, for example, MRI imaging can be used in real time to control or aid in guidance accuracy in an automated or semi-automated fashion.

In some implementations, thermography (e.g., MR thermography, ultrasonic thermography, etc.) provides contemporaneous temperature feedback regarding one or both of the targeted region and the surrounding tissue during the ITT process. The temperature information, for example, can be used to monitor necrosis of tumor tissue while ensuring that surrounding (healthy) tissue suffers minimal to no damage. The temperature feedback, in some implementations, is used to perform either or both of: automating engagement of the ultrasonic energy and cooling functionality of the ultrasonic applicator. In this manner, it is possible to control a temperature distribution or thermal dose in and around the tumor.

A system in accordance with this disclosure incorporates magnetic resonance imaging (MRI) compatible energy emission probes and/or other treatment devices and accessories for effective and controlled delivery of thermal therapy to a wide range of locations and tumor sizes within a brain. The system, however, is not limited to MRI-guided thermal therapy, as other therapies such as computer tomography (CT) can also be utilized. Further, this disclosure refers to an MRI scanner as an example medical imaging machine, which may be referred to simply as an MRI.

I. Overview

The interface platform 102 is secured to a patient table 108 of an MRI system 110. The MRI system 110 may include a head coil and stabilization system (herein stabilization system), an instrument adaptor, and an MRI trajectory wand. Exemplary MRI systems that can be utilized together with the features discussed herein include those manufactured by Siemens AG, Munich, Germany (including the MAGNETOM AVANTO, TRIO, ESPREE, VERIO MRI Systems, which are trademarks and/or trade names of Siemens AG). Further, example MRI systems include those manufactured by General Electric Company, Fairfield, Conn. (including the SIGNA, OPTIMA and DISCOVERY MRI systems, which are trademarks and/or trade names of General Electric Company).

In certain embodiments, all of the above components of the interface platform 102 and the energy emission therapy equipment are MRI compatible, which refers to a capability or limited capability of a component to be used in an MRI environment. For example, an MRI compatible component operates and does not significantly interfere with the accuracy of temperature feedback provided by the MRI system operating with exemplary flux densities including: magnetic flux densities of 1.5 T or 3.0 T, where no hazards are known for a specified environment (e.g., 1.5 T or 3.0 T). Compatibility can also be defined with respect to one or more other magnetic flux densities, including at least 0.5 T, 0.75 T, 1.0 T, 2 T, and 5 T.

In certain embodiments, the system electronics rack 104 includes cables, penetration panels and hardware that effectuates mechanical, electrical, and electronic operation of the energy emission therapy equipment and the MRI system 110. The system electronics rack 104 may further be used to power and route control signals and/or communications for the control workstation 106.

The workstation 106 includes a display that displays a user interface, e.g., a graphical user interface (GUI) and/or a command line interface that enables a user to plan a treatment procedure and interactively monitor the procedure, the interface platform 102, and the entire MRI system 110. In certain embodiments, the user interface also provides the user, e.g., a medical professional, the ability to directly control the energy emission therapy equipment including an energy source associated therewith, and therefore, enables directly control of the application of the therapy to the patient.

Turning to FIG. 2, an exemplary position of a patient on the patient table 108 of the MRI system 110 is illustrated. The interface platform 102 is secured to the patient table 108 together with a head coil 202 and stabilization system, which is a head fixation device that immobilizes a patient's head. The stabilization system includes a head fixation ring 204. A probe 206 and probe driver 208 are coupled to probe introduction equipment 210, and to the interface platform 102 via umbilicals. A cable, for example, can be used to provide data, laser, fluid, etc. connections between the probe 206, probe driver 208, and interface platform 102 and the electronics rack 104 in the MRI equipment room (as illustrated in FIG. 1).

The probe introduction equipment 210, in certain embodiments, includes at least a portion that is detectable by the MRI system (e.g., included in temperature data that is displayed by an imaging portion of the MRI system) and is used for trajectory determination, alignment, and guidance of the probe 206. An MRI trajectory wand (e.g., an MRI detectable, fluid-filled tube) may be placed into the probe introduction equipment 210, for example, to confirm a trajectory, associated with an intended alignment, to a targeted tissue region, via MRI. After confirmation, the probe 206 may be introduced into the probe introduction equipment 210 to effect surgery or therapy.

The probe 206 may be composed of MRI compatible materials that permit concurrent energy emission and thermal imaging, and can be provided in multiple lengths, cross-sectional areas, and dimensions. Types of probes that can be utilized with the components and procedures discussed herein include RF, HIFU, microwave, cryogenic, and chemical release probes; the chemical release probes may include photodynamic therapy (PDT), and drug releasing probes. Treatments in accordance with the descriptions provided in this disclosure include treatments that ablate (i.e., “treat”) a tissue to destroy, inhibit, and/or stop one or more or all biological functions of the tissue, or otherwise cause cell damage or cell death that is indicated by a structural change in cells of the targeted tissue area. Ablation can be effected by laser, RF, HIFU, microwave, cryogenic, PDT and drug or chemical release. A corresponding probe and/or other instrument, such as a needle, fiber or intravenous line can be utilized to deliver one or more of these ablation agents intracorporeally or percutaneously and proximate to, in the vicinity of, abutting, or adjacent to a targeted tissue area so as to effect treatment. The probe 206 can be a gas-cooled probe so as to control delivery of the energy to the targeted tissue area. The length and diameter of the probe 206 is preselectable based on the targeted tissue area and/or the ROI. The probe 206, in some particular examples, can be a laser delivery probe that is used to deliver laser interstitial thermal therapy or a HIFU applicator that is used to deliver HIFU interstitial thermal therapy.

The probe driver 208 controls positioning, stabilization and manipulation of the probe 206 within a specified degree of precision or granularity. Turning to FIG. 3, the components of the probe driver 208 generally include a commander 302, umbilicals 304, a follower 306, and a position feedback plug 308 that receives position feedback signals from, for example, potentiometers within the follower 306. The probe 206 (illustrated in FIG. 2) can be inserted into the follower 306, and the follower 306 can control a rotational and longitudinal alignment and/or movement of the probe 206. The probe driver 208 can further include a rotary test tool (not illustrated) that can be used during a self-test procedure to simulate attaching a probe to the follower 306. An exemplary probe driver that can be utilized in accordance with the various aspects presented in this disclosure is described in U.S. Pat. No. 8,728,092 to Qureshi, entitled “Stereotactic Drive System” and filed Aug. 13, 2009, the entirety of which is incorporated herein by reference.

The probe driver 208 (illustrated in FIG. 2) is mounted to the interface platform 102. The position feedback plug 308 (illustrated in FIG. 3) connects to the interface platform 102 in order to communicate the position of the probe 206 to the user and/or the workstation 106 (illustrated in FIG. 1). The probe driver 208 is used to rotate or translate, e.g., by extending or retracting the probe 206. The probe driver 208, in a particular example, can provide, at a minimum, a translation of 20-80 mm, 30-70 mm, 40-60 mm or 40 mm, with a maximum translation of 60 mm, 80 mm, 100 mm, 120 mm or 60-150 mm. The probe driver 208, further to the example, can also provide, at a minimum, a rotation of 300°-340°, with a maximum rotation of 350°, 359°, 360°, 540°, 720° or angles therebetween.

Returning to FIG. 1, in certain embodiments, the workstation 106 outputs signals, to the MRI system 110 to initiate certain imaging tasks. In other implementations, the workstation 106 outputs signals to an intermediary system or device that causes the MRI system 110 to initiate the imaging tasks. In certain embodiments, the workstation 106 additionally outputs signals to the electronics rack 104. The electronics rack 104 includes various actuators and controllers that control the thermal therapy devices, such as, in some examples, a cooling fluid pressure and/or a flow rate of the cooling fluid, and a power source that powers a thermal therapy device. In one example of a thermal therapy device, the power source is a laser source that outputs laser light via an optical fiber. As illustrated in FIG. 1, the electronics rack 104 is located in an MRI Equipment Room and includes storage tanks to hold the cooling fluid, one or more interfaces that receive the signals from the control workstation 106 and/or a separate MRI workstation, an energy emission source (e.g. laser), and an output interface. One or more of the interfaces are connected with or include physical wiring or cabling that receives the signals and transmits other signals, as well as physical wiring or cabling that transmit energy to corresponding components in the MRI Scan Room through a portal that routes the signals and/or energy in a manner that minimizes any interface with or by the MRI system 110. The wiring or cabling are connected at or by the interface platform 102 to corresponding components to effect and actuate control of a thermal therapy device and/or an associated thermal therapy session.

In certain embodiments, the system is indicated for use to ablate, necrotize, carbonize, and/or coagulate the targeted tissue area (e.g., an area of soft tissue) through interstitial irradiation or thermal therapy, in accordance with neurosurgical principles, with a HIFU thermal therapy device. The HIFU thermal therapy device or probe includes ultrasonic transducers for directing ultrasonic energy at the targeted tissue area, causing the tissue to heat. The ultrasonic beam of the HIFU probe can be geometrically focused (e.g., using a curved ultrasonic transducer or lens) or electronically focused (e.g., through adjustment of relative phases of the individual elements within an array of ultrasonic transducers). In an ultrasonic transducer array, the focused beam can be directed at particular locations, allowing treatment of multiple locations of an ROI without mechanical manipulation of the probe. The depth of treatment can be controlled by adjusting the power and/or frequency of the one or more transducers of the HIFU probe.

In certain embodiments, either additionally or alternatively to HIFU thermal therapy, a laser-based thermal therapy is utilized in the MRI system. Laser probes of a variety of outputs can be utilized, including, in some examples, laser probes emitting laser light having wavelengths of 0.1 nm to 1 mm, and laser probes emitting laser light in one or more of the ultraviolet, visible, near-infrared, mid-infrared, and far-infrared spectrums. Types of lasers used with respect the laser probe include, for example, gas lasers, chemical lasers, dye lasers, metal-vapor lasers, solid-state lasers, semiconductor lasers, and free electron lasers. In a particular example, one or more wavelengths of the laser light emitted by the laser probe are within the visible spectrum, and one or more wavelengths of the laser probe are within the near-infrared spectrum.

In certain embodiments, the environment 100 can be utilized for planning and monitoring thermal therapies effected via MRI-imaging, and can provide MRI-based trajectory planning for the stereotactic placement of an MRI compatible (conditional) probe. The environment 100, in certain embodiments provides real-time thermographic analysis of selected MRI images and thus, temperature feedback information and/or thermal dose profiles for the targeted tissue area. For example, thermographic analysis of the MRI images can provide real-time verification of cellular damage in a targeted tissue area that corresponds to necrosis, carbonization, ablation, and/or coagulation. In another example, thermographic analysis can be used to monitor tissue surrounding a periphery of an ROI to ensure minimal if any damage to healthy tissues. Components of the environment 100 may assist in guiding, planning, adjusting, performing and confirming a thermal therapy session and trajectories associated therewith.

A procedure includes, generally, identifying an ROI and/or associated targeted tissue areas in a patient that should be treated, planning one or more trajectories for treating the tissue, preparing the patient and components for the treatment, and performing the treatment. Aspects of the various parts of the treatment are described throughout this disclosure, and an exemplary sequence of treatment steps is illustrated in FIGS. 4A and 4B.

Turning to FIG. 4A, a process flow diagram illustrates an exemplary method 400 for pre-planning a treatment of a patient. In pre-planning the thermal therapy session, in certain embodiments, pre-treatment Digital Imaging and Communications in Medicine (DICOM) image data is loaded and co-registered, for example, via the workstation 106 (illustrated in FIG. 1). Using the DICOM image data, one or more ROIs and/or targeted tissue areas and one or more initial trajectories can be determined and set (402).

In preparation for treatment, in certain embodiments, a head coil and fixation system is attached to the patient (404), for example by positioning the head coil and stabilization system on the surgical table. The patient can be immobilized using a head fixation ring. To ensure stable imaging, for example, the patient's head can be secured with the head fixation ring and remain fixed for the entire imaging portion of the flow chart in FIG. 4A. An example head fixation system is described in U.S. Provisional Application Ser. No. 61/955,124 entitled “Image-Guided Therapy of a Tissue” and filed Mar. 18, 2014.

Prior to applying thermal energy to an ROI, a probe entry location into the skull is identified. In certain embodiments, a burr hole is drilled in the skull (406). The burr hole may be drilled prior to attachment of probe introduction equipment (e.g., a miniframe, anchoring device, guide stem, instrument sheath, etc.). A twist-drill hole, in certain embodiments, can be created following a trajectory alignment of the probe introduction equipment. The twist-drill hole can have a size of 1-5 mm, 2 mm, 3 mm, 4 mm or 4.5 mm.

The probe introduction equipment, such as a stereotactic miniframe or low profile anchoring device, in certain embodiments, is attached to the patient's head (408). Probe aligning equipment, such as the miniframe or guide stem, can then be aligned along the intended trajectory, for example using image-guided navigation. After attaching the probe introduction equipment, the head coil can be attached. An exemplary head coil system is described in U.S. Provisional Application Ser. No. 61/955,124 entitled “Image-Guided Therapy of a Tissue” and filed Mar. 18, 2014. Depending on a process flow that is specific to a surgical center, the interface platform may be attached prior to or after MRI trajectory confirmation. The order of steps in a site-specific process may be determined based on members of MRI or surgical support team and may be determined during on-site training with respect to the MRI system. The interface platform (IP) is attached to the head end of the head coil and stabilization system. Then, the IP power and motor plugs are connected.

In certain embodiments, the patient is positioned in a MRI cabin, and MRI imaging is performed to confirm a trajectory (410) associated with a thermal therapy device and/or probe introduction equipment. For example, an MRI trajectory wand may be inserted into the probe introduction equipment for use in confirming its trajectory. The trajectory of the probe introduction equipment, for example, can be evaluated using MRI imaging prior to inserting a probe into the brain. Volumetric imaging or volumetric visualization may be captured to include the entire head and full extent of the probe introduction equipment, independently of ablation. Along with trajectory confirmation, in some examples, beam fiducial marker detection may also be performed. For example, the captured images may also display a position of a beam fiducial marker located in a portion of the probe introduction equipment. This marker can be detected and identified by the MRI imaging system and method to store an orientation of the physical direction of the probe. The captured images, in implementations where pre-treatment image data is not available, can be used for planning a thermal therapy session.

In certain embodiments, a probe actuation and guidance device (e.g., a follower) and a test tool are attached to the probe introduction equipment, to provide positional feedback for a self-test function (412). The self-test function, for example, may be used to confirm that inputs to the probe actuation and guidance device, (e.g., from the workstation), accurately and/or precisely drive the probe. Upon completing the self-test function, the rotary test tool may be removed. Upon completing the procedure described in relation to FIG. 4A, the procedure equipment may be introduced and the procedure initiated.

Turning to FIG. 4B, a process flow diagram illustrates an exemplary method 420 for a treatment procedure. In certain embodiments, a probe is attached and inserted into the probe introduction equipment and/or the patient's skull (e.g., secured for manipulation via the probe actuation and guidance device) (422). Exemplary implementations of neurosurgical probes are discussed in below under the section entitled “Probes.” It is noted that different types of probes can be used in conjunction different types of thermal therapy, for example, when an ROI is not in the brain. An MRI scan can then be conducted to ensure probe alignment is correct and confirm movement and delivery of the probe along the intended trajectory. In one example, the acquired image data can be displayed, along with pre-planning image data by the workstation 106. Using a graphical user interface (GUI), a user can adjust the probe displayed by the GUI by interacting with, for example, the GUI to match the probe artifact on the acquired image to ensure that the alignment and arrangement of the probe as physically placed in the probe introduction equipment and inserted into the patient coincides with the rendered probe at the workstation. The probe's trajectory, for example, can be adjusted to a desired position for delivering thermal energy, via interaction with the GUI. Further, the probe's rotational position can also be adjusted to a desired direction or angle for thermal delivery, via interaction with the GUI. Once the probe rendering presented by the GUI matches the probe artifact on the display, the user may confirm the trajectory via the GUI.

In certain embodiments, one or more scan planes are selected for curing a thermal monitoring sequence via the MRI system's sequence protocol list (424). In another embodiment, a 3D volume is selected and in yet another embodiment, a linear contour is selected. Parameters associated with scan plane, in some examples, can be entered by a user via a workstation connected with the MRI system or directly into the thermal monitoring sequences protocol's geometry parameters of the MRI.

In certain embodiments, temperature feedback information and/or thermal dose profiles are initialized and monitored (426). For example, under a noise masking heading of the workstation interface, at least three reference points (e.g., six, twelve, twenty, etc.) can be selected by the user at the periphery of the ROI. The ROI, for example, may include an overlaid, orange noise mask in one or more image monitoring view panes to illustrate the intended thermal delivery area. The noise masking may be used to improve accuracy of temperature monitoring during tissue treatment.

In certain embodiments, energy delivery via the probe is actuated to begin the thermal therapy session (428). For example, once “Ready” indicator or the like is displayed under a laser status heading of the GUI at the workstation, the user may depress a foot pedal operatively connected to the workstation to deliver thermal energy to the ROI or a targeted tissue area within the ROI. Thermal energy can then be either continuously or intermittently delivered while monitoring thermal dose profiles, which can be presented as contours that are overlaid onto one or more (e.g., three) thermal monitoring view panes rendered by the GUI of the work station. Thermal delivery may be halted as desired or as necessary by releasing the foot pedal. The view panes, for example, may display an energy dose profile or thermal dose profile supplied by the probe, with respect to a specified time period and/or a specified targeted tissue area or ROI; the thermal dose or energy dose profile can be displayed as a succession of temperature gradients. The thermal dose profiles and/or the temperature gradients permit the determination of an extent of cellular damage in the targeted tissue area and/or other effects upon the targeted tissue area occurring as a result of the thermal therapy.

Once a thermal dose for a particular alignment and positioning of the probe is completed, if further probe alignments are desired within the treatment plan (430), a rotational and/or linear alignment of the probe may be adjusted (432) by translating or rotating the probe. For example, an energy output of the probe may be terminated and then the probe may be subjected to linear translation and/or rotational movement, which can be controlled, for example, by a probe driver (a particular implementation of which is illustrated in FIG. 3). After adjusting the probe alignment, in certain embodiments, the process returns to step 422 to verify a current placement of the probe. In certain embodiments, a second thermal treatment procedure is not initiated (e.g., when repeating step 428) until one or more targeted tissue areas within the ROI returns to a baseline body temperature. The thermal dose associated with the one or more targeted tissue areas in the ROI, as described in relation to steps 422 through 432, may continue at various probe rotational and/or linear alignments until the entire ROI has been treated.

Upon determining that the thermal therapy is complete (430), should treatment with an additional probe be needed or desired (434), the procedure can be repeated by attaching the new probe to the probe introduction equipment and verifying probe placement (422). If, instead, the second probe was initially included within the probe introduction equipment (e.g., via a separate lumen in a guide sheath in relation to the first probe), the user may initiate positioning of the second probe, for example, via the GUI, and verify placement of the second probe (422). A multi-probe configuration is described in greater detail in relation to FIG. 5I.

If the second probe is being deployed to treat the same ROI or the same targeted tissue area at the same linear and rotational alignment(s) associated with the first probe, in certain embodiments, step 424 involving selection of scan planes for the curing the thermal monitoring sequence may be skipped. If, instead, a second probe is deployed at a different linear position or a different trajectory, step 422 may be performed to confirm the trajectory and alignment of the second probe.

When the thermal therapy is complete (434), in certain embodiments, the patient is removed from the MRI bore and the probe, probe actuation and guidance device, and probe introduction equipment are detached from the patient. The bore hole may be closed, for example, at this time.

II. Low Profile Probe Introduction Equipment

A. Low Profile Skull Anchoring Device

In certain embodiments, when preparing for an intracranial neurosurgical procedure, a patient 502 is fitted with a low profile skull anchoring device 504, as illustrated in an exemplary mounting illustration 500 of FIG. 5A. The low profile skull anchoring device 504 may be releasably attached to the head of the patient 502, for example, using three or more bone anchors mounted to the skull of the patient 502. Turning to FIG. 5B, the low profile skull anchoring device 504 includes three bone screws 508 for connecting to bone anchors within the skull of the patient 502, as well as pins 510 for further securing the low profile skull anchoring device 504 to the head of the patient 502 and for ensuring that the low profile skull anchoring device 504 mounts above the surface of the head of the patient 502. In this way, there will be minimal or no compression of the patient's scalp. In one embodiment, the low profile skull anchoring device 504 has an oval or an oblong shape.

In one embodiment, the screws 508 and pins 510 are composed of, for example, titanium. It should be noted that the screws 508 and the pins 510 are not necessarily limited to three pins; the number of screws 508 and pins 510 used is the number which is necessary to provide sufficient rigidity. The screws 508 and pins 510 may be evenly spaced around the circumference of the low profile skull anchoring device 504 (e.g., positioned approximately every 120 degrees). In another embodiment, the screws 508 and pins 510 are positioned at unequal distances apart, for example, based on an irregular skull curvature. In yet another embodiment, the screws 508 and the pins 510 are movable with respect to the low profile skull anchoring device 504. In still another embodiment, the screws 508 are replaced with a sufficiently rigid adhesive or a staple, each of which provide sufficient rigidity to allow for the drilling of a burr hole in the skull.

Due to the low height of the low profile skull anchoring device 504, the medical team is provided with greater access for lateral trajectories of biopsy, probes, and other apparatus to be inserted intracranially into the patient 502 via the low profile skull anchoring device 504. This may be especially useful when working within the confines of an MRI bore, for example during MRI-guided thermal therapy treatments. As such, the low profile skull anchoring device 504 may be composed of MRI compatible materials and, optionally, include MRI visible markers for aligning a desired trajectory or defining a particular direction relative to the low profile skull anchoring device 504. In another example, the low profile skull anchoring device 504 may allow easier access to back-of-the-head entry trajectories, such as trajectories used in performing epilepsy treatments. A mounting height of the low profile skull anchoring device 504, for example, may be thirty millimeters or less from the surface of the skull of the patient 502.

B. Removable Guide Stem

Turning to FIG. 5A, the low profile skull anchoring device 504 includes a removable guide stem 506. The removable guide stem 506, in some examples, may lock to the low profile skull anchoring device 504 using a screw mechanism, keyed locking mechanism, or other connector configured to firmly connect the removable guide stem 502 to the low profile skull anchoring device 504 with relative ease of removal.

Turning to FIG. 5B, the exemplary the low profile skull anchoring device 504 includes three connection points 512 for securing the removable guide stem 506 to the low profile skull anchoring device 504. The removable guide stem 506, for example, may include a series of guide stem connectors 514 (e.g., screws or locking pins) which mate with the connection points 512 of the low profile skull anchoring device 504, as shown in FIGS. 5A and 5C. In one embodiment, the alignment of the guide stem connectors 514 and the connection points 512 differs based on a skull curvature of the patient.

In another example, the removable guide stem 506 may lock to the low profile skull anchoring device 504 using a keyed mechanism, such as an insert-and-twist slot and tab configuration (not illustrated). In still further examples, the removable guide stem 506 may releasably connect to the low profile skull anchoring device 504 using retractable locking pins which mate to corresponding depressions. For example, retractable pins built into the low profile skull anchoring device 504 may be extended to mate with corresponding depressions within the removable guide stem 506. In another example, spring-loaded retractable locking pins may be pressure-inserted into mating depressions within the removable guide stem 506, for example by pushing the removable guide stem 506 into the interior diameter of the low profile skull anchoring device 502. Further to this example, a latch or button mechanism may be used to retract the locking pins and release the removable guide stem 506 from the low profile skull anchoring device 502. Other locking mechanisms are possible.

A central cylindrical portion of the removable guide stem 506 is configured to receive various adapters and/or instruments such as, in some examples, drill bits, biopsy needles, and treatment probes. The central cylindrical portion of the removable guide stem 506, in certain embodiments, is rotatably adjustable, allowing an orientation of central cylindrical portion of the removable guide stem 506 to be manipulated to align the probe in accordance with a desired trajectory. Upon alignment, in certain embodiments, a locking mechanism 516 may be actuated to lock the central cylindrical portion of removable guide stem 506 into place at the set alignment.

Turning to FIG. 5C, the removable guide stem 506 may include, for example, a ball joint 518 for establishing an adjustable trajectory for passing instruments to the skull of the patient 502 via the central cylindrical portion of removable guide stem 506. In certain embodiments, the central portion has another geometric or polygonal shape that corresponds to a cross-section of the probe. In certain embodiments, interior portions of the central cylindrical portion of the removable guide stem 506 are deformable so as to cover an outer surface of the probe. In still other embodiments, the interior portions of the central cylindrical guide stem are comprised of shape memory alloys that have a transition temperature that exceeds a maximum temperature associated with a specified thermal therapy.

The ball joint 518 can achieve a number of trajectories that is based on the granularity with which the ball joint 518 is manipulated. Upon setting the trajectory of the central cylindrical portion of removable guide stem 506, for example, the ball joint 518 may be clamped into position using the locking mechanism 516. In one embodiment, the locking mechanism 516 is a cam lock. In another embodiment, the locking mechanism 516 is a ring clamp. In still another embodiment, the locking mechanism 516 has a screw engagement. In another example, the ball joint 518, upon positioning of the trajectory, may be clamped into position using a ring clamp (not illustrated).

In some implementations, the ball joint may be perforated and/or indented at set increments such that, rather than an infinitely adjustable trajectory, the removable guide stem 506 has a multiple selection trajectory allowing for precise adjustment. Upon positioning, for example, a screw engagement or locking pin may lock the ball joint 518 at the selected position. Further to the example, to aid in precision adjustment, guide lines or trajectory markers may indicate a selected trajectory (e.g., in relation to a plane of the low profile skull anchoring device 504).

Turning to FIGS. 5D and 5E, illustrative examples of a removable guide stem 520 including both a tilt adjustment 522 and a rotation adjustment 524 are shown. The separate tilt adjustment 522 and rotation adjustment 524, for example, may be used to more precisely adjust a trajectory of the central cylindrical portion of removable guide stem 520. Upon adjusting the tilt adjustment 522, for example, a tilt lock mechanism 526, such as a screw and hole or locking pin and pin slot, may be activated to hold the central cylindrical portion of removable guide stem 520 at the selected tilt position. In another example, upon adjusting the rotation of the central cylindrical portion of removable guide stem 520, for example by turning the rotation adjustment 524, a rotation lock mechanism 528, such as a screw and hole or locking pin and pin slot, may be activated to hold the removable guide stem 520 at the selected rotation.

In other implementations, the tilt adjustment 522 and/or rotation adjustment 524 includes a graduated friction lock, such that asserting pressure along the line of adjustment causes the trajectory to “click” to a next incremental setting (e.g., one, two, or five degrees). In this circumstance, a user can count a number of clicks to determine a present relative trajectory selected. In one embodiment, the graduated friction lock includes a rack and pinion mechanism. In another embodiment, the graduated friction lock includes detents and a spring-loaded plunger.

In certain embodiments, guide lines such as a set of guide lines 530 are marked on the removable guide stem 520 (or the removable guide stem 506 illustrated in FIG. 5A) to provide a user with an indication of the selected trajectory. For example, an angle of tilt in relation to the low profile skull anchor 504 may be selected via the guide lines 530 (e.g., within a one, two, or five degree angle of adjustment). The guide lines 530, in certain embodiments, are MR indicators, such that an MR image captured of the removable guide stem 520 will allow a software package to register an initial trajectory in relation to the head of the patient (e.g., patient 502 of FIG. 5A).

In certain embodiments, in addition to a tilt and rotation adjustment, either the first removable guide stem 506 or the second removable guide stem 520 may be modified to include an x,y degree of freedom adjustment mechanism (not illustrated). In this manner, a position of the central cylindrical portion of guide stem 506 in relation to a burr hole opening beneath the low profile skull anchor 504 may be adjusted by the user. Rather than the central cylindrical portion of guide stem 506 or 520 being centered within the low profile skull anchor 504, for example, an x,y adjustment mechanism may allow an offset of the central cylindrical portion of removable guide stem 506 or 520. In a particular example, should the burr hole fail to be centered between bone anchors planted within the skull of the patient 502, the central cylindrical portion of guide stem 506 or 520 may be adjusted by up to at least ten to twenty millimeters to be centered above the burr hole using an x,y adjustment mechanism.

For example, the x,y adjustment mechanism may be configured using an adjustable spring loaded cam and locking mechanism (e.g., set pin or screw). In another example, the x,y adjustment mechanism may be configured using an adjustable hinge configuration, such that the legs of the “Y” shape of the guide stem 506 are capable of swinging along an adjustment travel of the hinge configuration.

In some implementations, the guide stem 506, rather than being fixedly connected to the low profile skull anchor 504, may be adjustably connected to the low profile skull anchor 504. For example, the guide stem 506 may connect to an adjustable gantry system, such that the x,y displacement of the guide stem 506 can be set through an adjustable gantry. In a further example, the x, y adjustment mechanism can be configured using a rotatable ring configured between the low profile skull anchor 504 and the guide stem 506, such that the Y shape of the guide stem 506 may be twisted to a desired trajectory and then the guide stem 506 may be adjusted closer to the low profile skull anchor 504 along an adjustment leg of the Y shape. For example, an adjustment mechanism may be provided along a particular leg of the Y shape such that, to implement x,y adjustment, the Y is first rotated into a desired position, and then linear travel effected along the adjustment branch of the Y.

In some implementations, rather than a Y-shaped removable guide stem mechanism such as guide stem mechanism 506, the removable guide stem mechanism includes an X-shaped connection to aid in x,y adjustment. In this configuration, the x,y adjustment mechanism can include a slideable gantry with locking mechanisms such as a clamp or set screw. In another example, the x,y adjustment may include a screw drive, allowing a user to twist and adjust the displacement of the central position of the guide stem 506 in either or both the x direction and the y direction. Further, the spring-loaded cam and/or hinge system adjustment mechanisms described above in relation to the Y-shaped configuration are equally applicable to an X-shaped configuration.

Turning to FIG. 5B, upon removal of the removable guide stem 506 or 520, the skull entry location becomes accessible, for example to allow for formation of a burr hole or to otherwise prepare the skull entry location. After preparation of the entrance, the removable guide stem 506 or 520 may be locked to the low profile skull anchor 504. For example, as illustrated in FIG. 5D, the removable guide stem 520 may be locked to the low profile skull anchor device 504 by attaching screws at three connection locations 532. In another example, the removable guide stem 520 may be clamped to the low profile skull anchor device 504. At any point in a procedure, should access to the entrance be desired, the guide stem 520 may be removed. Removal of the guide stem 520, for example, allows a medical professional quick access to react to bleeding or to adjust the burr hole opening for trajectory correction.

When performing a medical procedure via the low profile skull anchoring device 504, in certain embodiments, the low profile skull anchoring device 504 may first be aligned with screw anchors mounted upon the patient's skull and then screwed to the head of the patient 502, as illustrated in FIG. 5A. The skull entry location may be prepared for treatment during the thermal therapy while the removable guide stem 506 or 520 has been separated from the low profile skull anchoring device 504. Following preparation of the skull entry location, the removable guide stem 506 or 520 may be replaced and its trajectory aligned.

To align the removable guide stem 506, 520 with a desired treatment trajectory, in certain embodiments, the removable guide stem 506, 520 is automatically manipulated. For example, the removable guide stem manipulation may be performed by software executing upon the commander 302 of the probe driver 208 as described in relation to FIG. 3. In another example, the removable guide stem 506 may be manipulated via a trajectory planning module of a software system, such as software executing upon the workstation 106 of FIG. 1. The manipulations of the removable guide stem 506, 520, for example, may be performed by a probe actuation and guidance device. In a particular example, as described in relation to the method 400 of FIG. 4A, a test tool may be inserted into the removable guide stem 506, 520, and the test tool may be aligned with pre-treatment image data to determine an initial trajectory. In another example, automatic manipulation may be supplemented with real time images supplied by an image guided system (e.g., MRI-imaging system). For example, the test tool alignment may be monitored and verified by a software algorithm through capture of MRI images during manipulation. In other implementations, an operator manually adjusts the trajectory of the removable guide stem 506, 520. Alignment of the trajectory of the removable guide stem 506, 520, in some implementations, is aided by one or more guide lines or fiducial markers upon the surface of the low profile skull anchoring device 504 and/or upon the surface of the removable guide stem 506, 520, such as the guide lines 530 illustrated in FIG. 5D.

Upon positioning the trajectory of the removable guide stem 506, 520, in certain embodiments, the trajectory is locked via a locking mechanism, such as the locking mechanism 516 of FIG. 5C or the locking mechanisms 526 and 528 of FIG. 5D.

After the removable guide stem 502 has been locked into its initial trajectory, in certain embodiments, instruments may be guided into the skull via the removable guide stem 506 or 520. For example, biopsy tools, a thermal treatment probe, medicament delivery probe, or other neurosurgical device may be delivered to a ROI of the brain of the patient via the removable guide stem 506 or 520.

C. Trajectory Positioning

FIG. 6 is a flow chart illustrating an example method 600 for determining trajectory adjustments based upon initial position and orientation of probe introduction equipment upon the skull of a patient. The method 600, for example, may be used in determining a trajectory prior to conducting a neurosurgical procedure. In some implementations, the method 600 is performed by software executing upon the workstation 106, as described in relation to FIG. 1. In another example, the method 600 is performed by software executing upon the commander 302 of the probe driver 208 as described in relation to FIG. 3.

In some implementations, the method 600 begins with obtaining an MRI image of a skull of a patient fitted with probe introduction equipment (602). The MRI image, for example, may be obtained by the MRI system 110, as described in relation to FIG. 1. MRI image data including two or more images, in other examples, may be obtained from a remote medical system, for example through a hospital file transfer system. Further, MRI image data, in some implementations, may be scanned into the system and loaded into the software.

In some implementations, one or more fiducial markers identifying probe introduction equipment are determined from the MRI image (604). For example, a software system installed upon the workstation 106 can review the MRI image data for graphical data matching a known fiducial marker related to probe introduction equipment. For example, a particular shape or series of shapes may be indicative of the location of probe introduction equipment, such as the low profile skull anchoring device 504 described in relation to FIGS. 5A through 5E or the stereotactic miniframe described in U.S. patent application Ser. No. 13/838,310 to Tyc, entitled Image-Guided Therapy of a Tissue and filed Mar. 15, 2013, which is hereby incorporated by reference in its entirety.

In some implementations, if a type of the probe introduction equipment is unknown (606), a type of the probe introduction equipment may be determined based upon one or more of the shapes, sizes, lengths, and/or positions of the identified fiducial marker(s) (608). For example, based upon a particular arrangement or shape of fiducial marker, the software algorithm may differentiate the low profile skull anchoring device from the stereotactic miniframe. In another example, a particular arrangement of fiducial markers may be used to differentiate a low profile skull anchoring device with an x,y adjustment guide stem from a low profile skull anchoring device with an immobile guide stem.

In other implementations, the type of probe introduction equipment may be known (606). For example, the software may be bundled with particular probe introduction equipment such that the fiducial markers are only used to identify positioning of the known probe introduction equipment. In another example, a user may manually enter the type of probe introduction equipment into the software (e.g., through a drop-down selection menu or other selection mechanism). In a further example, a communication may be received from the probe introduction equipment by the software, identifying the type or model of probe introduction equipment. In a particular illustration of this example, an algorithm executing upon the commander 302 of the probe driver 208 (illustrated in FIG. 3) communicates information regarding the type of probe introduction equipment to the software.

Once the type of probe introduction equipment has been identified, in some implementations, a position and orientation of the probe introduction equipment is determined using the identified fiducial markers (610). For example, based upon a particular distribution of fiducial markers, the software may identify the mounting location of the probe introduction equipment in relation to the skull of the patient. Fiducial markers, as a particular illustration, may identify the relative locations of the bone screws 508 of the low profile skull anchoring device 504, as illustrated in FIG. 5B. In another example, the trajectory of the guide stem 506, as illustrated in 5C, may be determined based upon an angle of a fiducial marker line or shape upon the guide stem 506.

The position and orientation of the probe introduction equipment, in some implementations, is determined with reference to the skull of the patient. For example, identifying relative locations of the bone screws 508 based upon fiducial markers upon the low profile skull anchor 504 may identify position of the head of the patient. In another example, fiducial marker stickers may be applied to the head of the patient to identify the head relative to the probe introduction equipment. Features of the head of the patient, such as brow, ears, nose, or cheek bones, for example, may be highlighted to orient the position of the low profile introduction equipment in relation to the face of the patient.

In other implementations, position and orientation of the probe introduction equipment is determined relative to imaging or head stabilization equipment. In a first example, the position and orientation of the probe introduction equipment may be determined based upon one or more fiducial marker reference points on the head coil 202 or the head fixation ring 204, as illustrated in FIG. 2.

In some implementations, a position of a portion of the probe introduction equipment may be identified in relation to other probe introduction equipment. For example, as described in relation to the guide stems 506 and 520 of FIGS. 5A through 5E, an x,y degree of freedom adjustment mechanism may have been used to modify the position of the central cylindrical portion of guide stem in relation to a burr hole opening beneath the probe introduction equipment. If the central cylindrical portion of the guide stem is offset in relation to the low profile skull anchoring device 504, for example, the software may calculate the position of the offset.

In some implementations, a representation of the probe introduction equipment is overlaid on the displayed MRI image (612). For example, based upon the type, position, and orientation determined above, the software may overlay a reference image (e.g., semi-transparent image, dotted outline, etc.) representing the location of at least a portion of the probe introduction equipment. For example, a position and orientation of the guide stem 506 attached to the low profile anchoring device 504 (e.g., as illustrated in FIGS. 5A and 5C) may be presented to the user. The overlaid image, in some embodiments, mimics the look and design of the actual probe introduction equipment. In other embodiments, the overlaid image is a simple dotted line orientation image that may bear little similarity to the look of the actual equipment.

In some implementations, a target region of interest in the skull of the patient is determined (614). For example, as described in step 402 of the method 400, discussed with reference to FIG. 4A, pre-treatment image data may be used to identify one or more treatment regions of interest. In one example, a user may manually identify a region of interest, for example by highlighting or circling the region of interest within the MRI image. The region of interest, for example, may include a tumor or portion of a tumor. In some implementations, the region of interest is identified as a three-dimensional location within the skull of the patient. For example, the region of interest may identify a target point for a tip of a probe to reach. In other implementations, the region of interest may identify a three-dimensional volume. For example, the region of interest may describe a tumor or a portion of a tumor to be treated.

In some implementations, a trajectory is determined for reaching the target region of interest (616). For example, the software may identify an access path leading from the probe introduction equipment (as identified by via the fiducial markers) to the region of interest. The access path, in some implementations, depends upon features of the brain discerned to be within a general path leading from the probe introduction equipment to the target region of interest. The features avoided by the software, for example, may include the brain stem, particularly fibrous tissues or major arteries. To identify the features of the brain to avoid, in some implementations, the software analyzes MRI images of the patient to identify known delicate and/or difficult to traverse features. In other implementations, a user may highlight within scanned images of the patient's brain one or more features to avoid when selecting a trajectory.

In some implementations, the software identifies two or more potential access paths and selects between the access paths. For example, depending upon particularly delicate or difficult to maneuver features of the brain between the region of interest and the position of the probe introduction equipment, the software may select between two or more possible access paths to identify the path least likely to cause difficulties during the procedure. The two or more possible access paths, in one example, include a path to one end of a target volume versus a path to another end of a target volume. In another example, the two or more possible access paths include two or more curved access paths to a single target point. The curved access path, for example, may be determined based upon identification of therapeutic instruments that will be used during the procedure. For example, a user may identify a particular probe or other equipment capable of curved trajectory towards a region of interest. A pre-shaped probe, for example, may be designed to deploy from the probe introduction equipment 210 (e.g., a guide sheath or guide stem) at a particular angle of curvature. The software, for example, upon receiving identification of the probe being used, may access data regarding the angle of curvature of the selected probe. In another example, the software algorithm may recommend a deployment device (e.g., guide sheath, guide sleeve, etc.) including an offset distal opening at a particular angle to effect the desired curved trajectory of a flexible cannula or laser fiber. For example, as illustrated in FIG. 5I, the off-axis delivery hole 558 may be used to deploy the flexible cannula or laser fiber at a particular angle.

In some implementations, a flexible cannula or laser fiber can be automatically directed along a trajectory. For example, a flexible cannula or laser fiber may be capable of curved guidance using magnetic steering. In this example, one or more gradient coils may be used to guide the flexible cannula or laser fiber along a curved path to access a region of interest. In this example, the software may access capabilities of the magnetic steering system and flexible cannula or fiber to determine potential trajectory paths. Determining the trajectory, further to this example, may include determining commands to provide to a magnetic steering system to guide the flexible cannula or laser fiber to the region of interest.

In a further example, a robotic steering device such as a robotic worm may be used to pull a flexible neurosurgical instrument towards the region of interest along the curved access path. For example, the robotic worm may be remotely controlled to navigate a path towards a difficult to access region of interest while pulling or otherwise feeding the flexible neurosurgical device into position. In another example, the robotic worm may be programmed to follow a predetermined path to the region of interest such that, upon deployment (e.g., via a guide sheath or rigid cannula), the robotic worm steers the flexible neurosurgical instrument into position at the region of interest. The robotic worm, in some implementations, is further designed to create a path, for example through fibrous tissue, by cutting or bluntly pushing aside tissue to provide access for the flexible neurosurgical instrument. In some implementations, determining the trajectory includes determining commands to provide to the robotic worm to guide the flexible neurosurgical instrument to the region of interest.

In some implementations, one or more recommended adjustments for setting a trajectory of the probe introduction equipment are determined based upon the location of the region of interest and the initial position and orientation of the probe introduction equipment (618). In some implementations, the software identifies one or more adjustment features and/or ranges of motion of the particular type of probe introduction equipment. For example, using the guide stem 506 described in relation to FIG. 5C, the software may identify that the guide stem 506 has an infinitely adjustable trajectory via the ball joint, and based upon present orientation, to achieve the desired trajectory, a user may wish to align the guide stem 506 with particular guide lines. Similarly, based upon identification of the removable guide stem 520 having both the tilt adjustment 522 and the rotation adjustment 524, the software algorithm may identify two separate adjustments for setting the desired trajectory, both the tilt adjustment and the rotation adjustment (e.g., as identified by guide lines or other adjustment markers (or “clicks”) of the tilt adjustment 522 and/or the rotation adjustment 524).

If the probe introduction equipment includes an x,y degree of freedom adjustment mechanism for adjusting the position of the central cylindrical portion of guide stem in relation to the low profile skull anchoring device, the software may identify adjustment ranges of the x-y degree of freedom adjustment mechanism and recommend a modified offset of the guide stem to align with an optimal trajectory for reaching the region of interest.

In some implementations, the one or more recommended adjustments are provided for review by a medical professional (620). For example, the adjustments may be presented upon a display in communication with the workstation 106. In another example, the adjustments may be presented upon the display region of the interface platform 102 (as illustrated in FIG. 2) such that a user may review the instructions while setting the trajectory of the probe introduction equipment. In some implementations, in addition to the recommended adjustments, a displaced positioning of the representation of the probe introduction equipment may be overlaid on the displayed MRI image (e.g., illustrating the recommended alignment of the adjusted probe introduction equipment with the region of interest).

Using the recommended adjustments, for example, the medical professional may manually adjust the probe introduction equipment to the new trajectory. In other implementations, the probe driver 208 (illustrated in FIG. 3) and/or other automated equipment may be used instead or in coordination with manual adjustments to align the trajectory of the probe adjustment equipment. For example, the software may issue commands to the probe driver 208 to adjust a trajectory of the guide stem after receiving confirmation from a user that the guide stem locking mechanism is in an unlocked position. Upon positioning, the software may prompt the user to engage the locking mechanism, locking the guide stem into position.

After adjusting the trajectory, in some implementations, the user may request confirmation of desired trajectory via the software. To confirm the trajectory setting, for example, the software may compare present fiducial marker alignment with anticipated fiducial marker alignment (e.g., based upon change in position of the fiducial markers). In another example, the software may re-calculate a trajectory using the present fiducial markers and verify that the new trajectory aligns with the region of interest. The software, in a third example, may calculate an anticipated trajectory based upon the identified alignment (e.g., based upon a present position of the fiducial markers) and compare the anticipated trajectory to the trajectory calculated in step 616. Should the adjustment be misaligned for some reason, at least steps 616 and 618 of the method 600 may repeated as necessary.

D. Guide Sheath

Turning to FIGS. 5F and 5G, in certain embodiments, rather than inserting instruments directly into the removable guide stem 506 or 520, a guide sheath 540 is inserted into the removable guide stem (e.g., removable guide stem 506). The guide sheath 540 may include, for example, one or more distal openings and one or more proximal openings to introduce at least one neurosurgical instrument to the ROI in the patient's brain.

In certain embodiments, instead of using the guide sheath 540 configured for receipt of neurosurgical devices, a hollow trocar may be introduced via the removable guide stem 506 or 520 to prepare an initial entry into a region of the brain. For example, when entering a particularly fibrous area, rather than pushing in directly with a neurosurgical instrument and risking damage to the neurosurgical instrument, a trocar or stylette, may be used to cut a path for the neurosurgical instrument. The stylette or trocar, for example, may have a sharp distal opening to cut a path through the fibrous area. In another example, the trocar or stylette may have a bullet shaped nose to bluntly push tissue out of the trajectory path. In other implementations, a stylette or trocar may be introduced to the region of interest via the guide sheath 540.

In certain embodiments, the guide sheath 540 locks to the removable guide stem 506. The guide sheath 540, for example, may be configured to lock to the removable guide stem 506 at a variable linear height depending upon a distance between the skull opening and a ROI. In this manner, the guide sheath 540 may be deployed in proximity to, in the vicinity of, or adjacent to an ROI without abutting or entering the ROI. As such, upon removal of one or more neurosurgical instruments via the guide sheath 540, cells from the ROI will not be able to contaminate other regions of the patient's brain. In some implementations, a “wiper” mechanism designed into the distal end of the guide sheath 540 may aid in avoiding contaminants within the guide sheath 540.

Turning back to FIG. 5C, in certain embodiments, a guide stem locking mechanism 519 may be used to clamp the guide sheath 540 at a particular linear depth. The guide sheath 540, in a particular example, may have spaced indentations or other connection points for interfacing with the guide stem locking mechanism 519 (e.g., set screw or spring-loaded plunger). In other embodiment, the guide sheath may have spaced ratcheting teeth for interfacing with a ball plunger or toggle release. The indentations (or, alternatively, ratcheting teeth) may be positioned at precise measurements (e.g., 1 mm apart) to aid in linear position adjustment. In other examples, the guide sheath 540 and guide stem locking mechanism 519 may be configured to provide positive feedback to a medical professional during adjustment. For example, a linear actuator system such as a rack and pinion may be used to provide precise linear position adjustment (e.g., one “click” per millimeter). Upon adjustment, to lock the guide sheath 540 at the selected linear position, in certain embodiments a cam lock mechanism may be used to engage teeth or depressions within the guide sheath 540. For example, a cam lock mechanism such as the locking mechanism 516 illustrated in FIG. 5C may be used to lock the guide sheath 540 at a selected linear depth.

Turning back to FIG. 5D, the removable guide stem 520 similarly includes a guide stem locking mechanism 534. In other implementations, the guide sheath 540 may directly connect to the low profile skull anchoring device 504 or to another receiving port connected to the low profile skull anchoring device 504 (not illustrated).

The guide sheath 540, upon interlocking with the guide stem 506, 520 and/or the low profile skull anchoring device 504 and receiving one or more neurosurgical tools, may create an air-tight seal during a neurosurgical operation. For example, the proximal and/or distal end of the guide sheath 540 may include a receiving port adaptable to the surgical instrument being introduced. For example, the proximal and/or distal end of the guide sheath 540 may include an adjustable aperture that may be dialed or electronically set to a particular diameter matching a present neurosurgical instrument. In certain embodiments, various guide sheaths can be used interchangeably with the guide stem 506, 520, such that a guide sheath corresponding to the surgical instrument diameter may be selected. In other implementations, one or more guide sleeves (not illustrated) may be secured inside the guide sheath 540, each of the one or more guide sleeves having a different distal end diameter. A divided (e.g., bifurcated) guide sleeve, in certain embodiments, may be used to introduce two or more instruments simultaneously or concurrently, each with a particular instrument diameter.

In certain embodiments, the guide sheath 540 is intracranially delivered using an introducer and guide wire. An image guidance system, such as the MRI imaging system, may be used instead of or in addition to the introducer and guide wire during placement of the guide sheath 540. The guide sheath 540 may be composed of MRI compatible materials.

The materials of the guide sheath 540, in certain embodiments, are selected to provide rigid or inflexible support during introduction of one or more neurosurgical tools within the guide sheath 540. For example, the guide sheath 540 may be composed of one or more of Kevlar, carbon fiber, ceramic, polymer-based materials, or other MRI-compatible materials. The geometry of the guide sheath 540, in certain embodiments, further enhances the strength and rigidity of the guide sheath 540.

In certain embodiments, the guide sheath 540 (or guide sleeve, as described above) includes two or more lumens for introduction of various neurosurgical instruments. By introducing two or more neurosurgical instruments via the guide sheath 540, a series of treatments may be performed without interruption of the meninges layer between treatments. For example, FIG. 5I illustrates two neurosurgical instruments 552 and 554 that are simultaneously inserted into a guide sheath 550 and can be used to carry out treatment of a tissue consecutively, concurrently, or simultaneously.

Neurosurgical instruments deployed via the guide sheath 540 may exit a same distal opening or different distal openings. In certain embodiments, the guide sheath 540 may include at least one off-axis distal opening. For example, as illustrated in FIG. 5H, exemplary guide sheath 550 includes a contact surface 556 having a predefined angle. Upon encountering the contact surface 556, the trajectory of a surgical instrument 552 presented through the guide sheath 550 may be deflected to exit the proximal end via an off-axis delivery hole 558, as illustrated in FIG. 5I. The angles shown in FIGS. 5H and 5I can be considered as drawn to scale in one implementation. However, the alignment of the contact surface 556 and the delivery hole 558 can be varied by adjusting their respective axial angles. By adjusting these angles, a number of possible positions of the surgical instrument 554 are provided. Further, multiple off-axis delivery holes and multiple contact surfaces can be provided, which are displaced from each other in a direction of the longitudinal axis of the guide sheath.

Upon introducing a neurosurgical instrument such as a probe, in certain embodiments, the guide sheath 540 enables coupling between the probe and a probe actuation and guidance device. For example, commands for linear and/or rotational control of the probe may be issued to the probe via an interface within the guide sheath 540.

III. Probe

A number of different probes can be utilized in accordance with the various aspects presented in this disclosure. Example probes are described in: U.S. Pat. No. 8,256,430 to Torchia, entitled “Hyperthermia Treatment and Probe Therefor” and filed Dec. 17, 2007; U.S. Pat. No. 7,691,100 to Torchia, entitled “Hyperthermia Treatment and Probe Therefor” and filed Aug. 25, 2006; U.S. Pat. No. 7,344,529 to Torchia, entitled “Hyperthermia Treatment and Probe Therefor” and filed Nov. 5, 2003; U.S. Pat. No. 7,167,741 to Torchia, entitled “Hyperthermia Treatment and Probe Therefor” and filed Dec. 14, 2001; PCT/CA01/00905, entitled “MRI Guided Hyperthermia Surgery” and filed Jun. 15, 2001, published as WO 2001/095821; and U.S. patent application Ser. No. 13/838,310, entitled “Image-Guided Therapy of a Tissue” and filed Mar. 15, 2013. These documents are incorporated herein by reference in their entireties.

A number of probe lengths are provided in any of the probe examples described herein based on a degree of longitudinal travel allowed by a follower and a depth of the tissue to be treated. An appropriate probe length can be determined by the interface platform and/or the workstation during a planning stage, or determined during a trajectory planning stage.

Exemplary probe lengths can be indicated on the probes with reference to a probe shaft color, in which white can indicate “extra short” having a ruler reading of 113 mm, yellow can indicate “short” having a ruler reading of 134 mm, green can indicate “medium” having a ruler reading of 155 mm, blue can indicate “long” having a ruler reading of 176 mm, and dark gray can indicate “extra long” having a ruler reading of 197 mm. Different model numberings can also be utilized on the probes to indicate different lengths.

In general, a therapeutic window of wavelengths for thermal therapy using a laser probe ranges from 800 to 1100 nm. Wavelengths lower than 800 (e.g., within the visible spectrum) lack the energy to effectively heat tissue, while wavelengths above 1100 nm rapidly heat an immediate region, thereby being useful in applications such as tattoo removal where a thin region is burned. In some implementations, a laser probe has a 1064 nm wavelength for coagulation of tissue. The 1064 nm wavelength, for example, is selected based upon water absorption properties of laser wavelengths. By minimizing water absorption, for example, depth of penetration can be maximized. The 1064 nm laser probe, for example, may be used to apply thermal therapy to a three-dimensional zone approximately two to four centimeters in diameter. Thus, the 1064 nm wavelength allows deeper penetration and provides a higher power density associated with energy application so as to more efficiently effect thermal therapy. In certain embodiments, the laser probe is cooled via Joule-Thompson cooling, which eliminates and/or minimizes energy absorption and scatter, as discussed in further detail below.

In some implementations, the laser probe is a side-firing laser probe to focus the energy of the 1064 nm wavelength laser. For example, beyond the penetration zone of the laser probe (e.g., about two to four centimeters), the photon scattering can cause difficulties in focusing the therapy. Depth of penetration may be improved through focusing a laser beam using a side-firing design. Similar benefits may be achieved in designing a side-firing HIFU probe, as described below.

An energy output pattern of a probe, such as a laser probe or HIFU probe, in certain embodiments, includes a pulsed output pattern. For example, a higher power density may be achieved without causing tissue scorching by pulsing a high power laser treatment for x seconds with y seconds break between (e.g., allowing for tissue in the immediate vicinity to cool down). Furthermore, pulsing allows the system to vary energy delivered to a region of interest without affecting the power density applied to the region of interest. In this manner, higher energy can be applied to a region of interest without causing damage (e.g., scorching) to immediate tissue. In a particular example, the energy output pattern of a probe may include a ten Watt output for 2 to 2.5 seconds followed by a one to 1.5 second period of inactivity (e.g., delivering approximately 398 Joules per minute). In certain embodiments, a particular energy output pattern may be developed based upon the type of probe (e.g., laser, HIFU, etc.), an emission style of the probe tip (e.g., side-firing, diffuse tip, etc.), and/or the depth of the ROI and/or the targeted tissue area (e.g., based in part on the shape of a tumor region, etc.). For example, in a diffuse tip design, the energy output pattern for the diffuse tip probe may include a ten Watt output for 2 seconds, followed by a 0.3 second period of inactivity (e.g., delivering approximately 500 Joules per minute).

In some implementations, based upon feedback received through thermal imaging, the energy output pattern may be adjusted. For example, the period of inactivity may be lengthened or shortened depending upon a temperature gradient between the tissue closest to the probe and the depth of treatment (e.g., the furthest tissue being thermally ablated). In another example, the power output of the probe may be adjusted instead of or in addition to the period of inactivity, based upon thermal imaging feedback. For example, to increase a treatment radius, the power density supplied by the probe may be increased.

In some implementations, to further guard against tissue scorching, the laser probe may include a cooling tip to cool tissue within the immediate vicinity. During the period of inactivity between pulses, for example, the tip of the laser probe may cool to approximately 0 to 5 degrees Celsius. A cryogenic cooling device (e.g., cooling tube) may be designed into a 1064 nm wavelength side-firing laser probe, in a particular example, to affect cooling to surrounding tissue during inactive periods between energy pulses. A thermocouple within the cooling device, further to the example, can be read during inactive periods to avoid interference caused by energy emission. The 1064 nm wavelength allows deeper penetration and higher power density; that is, thermal therapy can cause cellular damage to a targeted tissue region in a shorter period of time.

In certain embodiments, a treatment pattern includes effecting treatment while concurrently or simultaneously moving the probe (e.g., linearly and/or rotationally). For example, a HIFU probe may be automatically rotated (e.g., using a commander and follower as described in FIG. 3, etc.) while an emission pattern is simultaneously or concurrently adjusted to effect treatment to a desired depth based upon a particular geometry of the ROI. In this manner, for example, while the ultrasonic probe's beam is focused on a radial portion of the tumor having a depth of 1.5 centimeters, the power density of the HIFU probe may be tuned for the first treatment depth. Upon rotation, a second radial portion of the tumor may have a depth of 2 centimeters, and the power density of the HIFU probe may be increased accordingly to tune for the treatment depth of 2 centimeters. If two or more ultrasonic transducers are included in the HIFU probe, the power may be varied on a per-transducer basis or to the entire transducer array.

A. Side-Fire HIFU Probe

Turning to FIG. 7A, a view 700 of an exemplary treatment scenario involving a HIFU probe 702 deployed to treat an ROI 706 is illustrated. HIFU technology advantageously provides directional control and greater depth penetration as compared with laser-based thermal therapy. For example, in comparison to laser therapy, ultrasonic therapy may achieve at least three to four times greater depth penetration. For example, estimated depths of thermal treatment using HIFU technology include three to five centimeters or greater than six centimeters. By completing treatment via an initial trajectory, the treatment may be performed faster and less invasively than it may have been performed using a laser probe. As such, a HIFU probe may be used to treat a larger ROI without the need to adjust a probe trajectory or introduce the probe into multiple locations within the brain. Although treatment may be provided at a greater depth, it also may be provided using a narrow focal beam, containing a width of the treated tissue. Furthermore, although HIFU-based thermal therapy can advantageously achieve a greater penetration depth than laser-based thermal therapy, the ultrasonic treatment has greater uniformity over temperature gradients than laser-based thermal therapy, which heats a portion of the targeted tissue area close to the probe much more rapidly than portions of the targeted tissue area further away from the probe. In selecting thermal therapy via a HIFU probe, scorching or carbonization of the targeted tissue area close to the probe may be avoided and/or the HIFU probe may be operated independently of external cooling to protect immediately surrounding tissue.

In performing thermal therapy using a HIFU probe, constructive and destructive interference can be utilized by selecting a number of different longitudinal spaced emission points to fine tune a position and depth of energy applied to a targeted tissue area and/or an ROI. As such, the depth of energy, as such, may be tuned to conform with a non-uniform, irregular, and/or non-polygonal shape of the ROI which, for example, corresponds to a tumor. For example, power supplied to the transducers of a side firing HIFU probe may be varied as the HIFU probe is rotated to a new position, thereby adjusting penetration of the ultrasonic energy to a depth of the a region of interest (e.g., tumor) at the present angle of rotation. In this manner, HIFU treatment may be used to “sculpt” an irregularly shaped three-dimensional lesion conforming to a region of interest through power variance during rotation of the probe. As noted above, because HIFU treatment may reach a penetration depth of three to five centimeters or even greater than six centimeters, it is imaginable that an irregularly-shaped tumor of at least 5 centimeters in diameter may be treated without the need to adjust an initial trajectory of the HIFU probe. In certain embodiments, the side-fire HIFU probe may treat an ROI having a tumor volume of up to 110 cubic centimeters. In other embodiments, the side-fire HIFU probe may treat an ROI having a tumor volume with a range of approximately 0.1 cubic centimeters and 110 cubic centimeters. Preparing trajectories, determining linear translational adjustments and/or rotational movements, and/or energy output patterns may be selected and/or optimized to prevent heating of the skull and/or bouncing energy off of the surfaces of the skull. HIFU treatment, in some examples, can be used for opening a blood-brain barrier, coagulation of tissue, or cavitation of tissue.

The HIFU probe 702 includes one or more side-firing transducers 704 for effecting treatment to the ROI 706. The ultrasonic transducer(s) 704 may be flat or rounded. The HIFU probe, in some examples, can include a shaft composed of plastic, brass, titanium, ceramic, polymer-based materials, or other MRI-compatible materials in which one or more ultrasonic transducer(s) 704 have been mounted. The ultrasonic transducer(s) 704 may be mounted upon an interior surface of the shaft of the HIFU probe 702. The ultrasonic transducer(s) 704 may include a linear array of individually controllable transducers, such that a frequency or power output of each transducer 704 may be individually tuned to control a treatment beam of the HIFU probe 702. For example, as illustrated in FIG. 7C, the tip of the probe 702 can include a linear array of three transducers 704. The longitudinally spaced apart transducers 704 can be spaced equally apart. However, in other implementations, the spacing between the transducers 704 can be unequal.

In certain embodiments, the HIFU probe 702 includes a cooling mechanism for cooling the ultrasonic transducers 704. For example, a cooling fluid or gas may be delivered to the tip of the HIFU probe 702 to control a temperature of the ultrasonic transducer(s) 704. Additionally, the ultrasonic transducer(s) 704 may be surrounded by an acoustic medium, such as an acoustic coupling fluid (e.g., water) to enable ultrasonic frequency tuning of the ultrasonic transducer(s) 704.

As illustrated in FIG. 7A, the HIFU probe 702 is embedded within an ROI 706 spanning multiple MR thermal monitoring planes 708. During treatment, thermal effects within each MR thermal monitoring plane 708 may be monitored in order to monitor thermal coagulation of the ROI 706. Information derived from the thermal monitoring, for example, may be fed back into control algorithms of the HIFU probe 702, for example, to adjust a power intensity and/or frequency of the HIFU probe to tune a depth of treatment of the ultrasonic beam or to adjust a rotational and/or linear positioning of the HIFU probe 702 upon determining that ablation is achieved at a current rotational and linear position.

To increase the monitoring region, additional MR thermal monitoring planes 708 may be monitored (e.g., between four and eight planes, up to twelve planes, etc.). Alternatively, in certain embodiments, the three thermal monitoring planes 708 may be spread out over the y-axis such that a first gap exists between plane 708a and plane 708b and a second gap exists between plane 708b and plane 708c. The thermal monitoring algorithm, in this circumstance, can interpolate data between the MR thermal monitoring planes 708.

In other implementations, rather than obtaining parallel images of MR thermal monitoring planes, at least three thermal monitoring planes, each at a distinct imaging angle bisecting an axis defined by a neurosurgical instrument such as a thermal ablation probe, may be interpolated to obtain thermal data regarding a three-dimensional region.

Turning to FIG. 8A, an aspect illustration 800 demonstrates three MR thermal monitoring planes 802 for monitoring ablation of an ROI 804 by a probe 806. The angles between the thermal monitoring planes, in some examples, may be based upon an anatomy of the region of the skull of the patient or a shape of the ROI. The angles, in some examples, may differ by at least ten degrees.

Turning to FIG. 8B, an end view 810 of the probe 806 provides an illustrative example of MR thermal monitoring planes 802 that are each offset by sixty degrees. In comparison to using parallel MR thermal monitoring planes, the thermal monitoring planes 802 provide a more realistic three-dimensional space. Temperature gradients and/or thermal dose profiles between the thermal monitoring planes 802 can be interpolated. Similar to increasing a number of parallel MR thermal monitoring planes, in other implementations, four or more thermal monitoring planes may be captured and combined, for example, to increase thermal monitoring accuracy.

As a result of the side-firing capability of the HIFU probe 702, a number of rotationally different portions of the ROI can be treated with the ultrasonic energy by rotating the HIFU probe 702. For example, as illustrated in an x-axis sectional view 710, the HIFU probe 702 may be rotated is illustrated in an arrow 712 to effect treatment throughout the ROI 706. Additionally, the HIFU probe 702 can be longitudinally translated, for example automatically by a follower of a probe driver, to change a longitudinal position at which ultrasonic energy is applied within the ROI 706.

Rotation, power intensity, duty cycle, longitudinal positioning, and cooling, in certain embodiments, are controlled by the electronics rack 104 and the workstation 106, such as the electronics rack 104 and workstation 106 described in relation to FIG. 1. A sequence, such as an algorithm or software encoding, can be executed to cause a probe tip or a number of probe tips to execute a particular energy output pattern effect a predefined thermal therapy to a targeted tissue area. The energy output pattern can be based on rotational and/or longitudinal movements of the probe.

The procedures and routines described herein can be embodied as a system, method or computer program product, and can be executed via one or more dedicated circuits or programmed processors. Accordingly, the descriptions provided herein may take the form of exclusively hardware, exclusively software executed on hardware (including firmware, resident software, micro-code, etc.), or through a combination of dedicated hardware components and general processors that are configured by specific algorithms and process codes. Hardware components are referred to as a “circuit,” “module,” “unit,” “device,” or “system.” Executable code that is executed by hardware is embodied on a tangible memory device, such as a computer program product. Examples include CDs, DVDs, flash drives, hard disk units, ROMs, RAMs and other memory devices.

FIG. 9 illustrates an example processing system 900, and illustrates example hardware found in a controller or computing system (such as a personal computer, i.e., a laptop or desktop computer, which can embody a workstation according to this disclosure) for implementing and/or executing the processes, algorithms and/or methods described in this disclosure. The processing system 900 in accordance with this disclosure can be implemented in one or more the components shown in FIG. 1. One or more processing systems can be provided to collectively and/or cooperatively implement the processes and algorithms discussed herein.

As shown in FIG. 9, the processing system 900 in accordance with this disclosure can be implemented using a microprocessor 902 or its equivalent, such as a central processing unit (CPU) and/or at least one application specific processor ASP (not shown). The microprocessor 902 is a circuit that utilizes a computer readable storage medium 904, such as a memory circuit (e.g., ROM, EPROM, EEPROM, flash memory, static memory, DRAM, SDRAM, and their equivalents), configured to control the microprocessor 902 to perform and/or control the processes and systems of this disclosure. Other storage mediums can be controlled via a controller, such as a disk controller 906, which can controls a hard disk drive or optical disk drive.

The microprocessor 902 or aspects thereof, in alternate implementations, can include or exclusively include a logic device for augmenting or fully implementing this disclosure. Such a logic device includes, but is not limited to, an application-specific integrated circuit (ASIC), a field programmable gate array (FPGA), a generic-array of logic (GAL), and their equivalents. The microprocessor 902 can be a separate device or a single processing mechanism. Further, this disclosure can benefit from parallel processing capabilities of a multi-cored CPU.

In another aspect, results of processing in accordance with this disclosure can be displayed via a display controller 908 to a display device (e.g., monitor) 910. The display controller 908 preferably includes at least one graphic processing unit, which can be provided by a number of graphics processing cores, for improved computational efficiency. Additionally, an I/O (input/output) interface 912 is provided for inputting signals and/or data from microphones, speakers, cameras, a mouse, a keyboard, a touch-based display or pad interface, etc., which can be connected to the I/O interface as a peripheral 914. For example, a keyboard or a pointing device for controlling parameters of the various processes and algorithms of this disclosure can be connected to the I/O interface 912 to provide additional functionality and configuration options, or control display characteristics. An audio processor 922 may be used to process signals obtained from I/O devices such as a microphone, or to generate signals to I/O devices such as a speaker. Moreover, the display device 910 can be provided with a touch-sensitive interface for providing a command/instruction interface.

The above-noted components can be coupled to a network 916, such as the Internet or a local intranet, via a network interface 918 for the transmission or reception of data, including controllable parameters. A central BUS 920 is provided to connect the above hardware components together and provides at least one path for digital communication there between.

The workstation shown in FIG. 1 can be implemented using one or more processing systems in accordance with that shown in FIG. 9. For example, the workstation can provide control signals to peripheral devices attached to the I/O interface 912, such as actuators 924 to drive probe positioning and actuation equipment. The workstation, in some implementations, can communicate with additional computing systems, such as an imaging unit 926 and/or an MRI unit 928, via the I/O interface 912.

One or more processors can be utilized to implement any functions and/or algorithms described herein, unless explicitly stated otherwise. Also, the equipment rack and the interface platform each include hardware similar to that shown in FIG. 9, with appropriate changes to control specific hardware thereof.

Reference has been made to flowchart illustrations and block diagrams of methods, systems and computer program products according to implementations of this disclosure. Aspects thereof are implemented by computer program instructions. These computer program instructions may be provided to a processor of a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

These computer program instructions may also be stored in a computer-readable medium that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable medium produce an article of manufacture including instruction means which implement the function/act specified in the flowchart and/or block diagram block or blocks.

The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide processes for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of this disclosure. For example, preferable results may be achieved if the steps of the disclosed techniques were performed in a different sequence, if components in the disclosed systems were combined in a different manner, or if the components were replaced or supplemented by other components. The functions, processes and algorithms described herein may be performed in hardware or software executed by hardware, including computer processors and/or programmable circuits configured to execute program code and/or computer instructions to execute the functions, processes and algorithms described herein. Additionally, some implementations may be performed on modules or hardware not identical to those described. Accordingly, other implementations are within the scope that may be claimed.

Claims

1. A method for effecting thermal therapy using an in vivo side fire laser probe, comprising: positioning the side fire laser probe in a volume in a patient at a target position;identifying a three-dimensional region of interest at which to apply thermal therapy; anddelivering, by processing circuitry, thermal therapy to the three-dimensional region of interest, wherein delivering thermal therapy comprises applying a pulsed energy output pattern by a) activating emissions exiting the side fire probe at a power output for a first period of time,b) deactivating emissions exiting the side fire probe for a second period of time, wherein the second period of time is selected to avoid tissue scorching, andc) repeating steps a) and b), while directing the pulsed energy output pattern in an initial trajectory until determining completion of thermal therapy at the initial trajectory, wherein the pulsed energy output pattern is delivered at a higher power density than achievable without causing tissue scorching using a constantly active energy output;wherein determining completion of thermal therapy at the initial trajectory comprises at least one of i) identifying the three-dimensional region of interest has reached a target temperature, and ii) identifying a thermal dose that is based on a temperature history of the three-dimensional region of interest over a specified time period.
2. The method of claim 1, further comprising, after determining completion of thermal therapy at the initial trajectory: positioning the side fire probe in the patient at a second target position by causing actuation of the side fire probe, by the processing circuitry, in at least one of a rotational direction and a linear direction; anddelivering, by the processing circuitry, thermal therapy to the three-dimensional region of interest by applying a second pulsed energy output pattern to the three-dimensional region of interest at a second trajectory corresponding to the second target position.
3. The method of claim 1, wherein the second period of time is at least 0.3 second.
4. The method of claim 1 wherein a wavelength of energy delivered by the side fire probe is 1064 nanometers.
5. The method of claim 1, wherein delivering thermal therapy to the three-dimensional region of interest further comprises activating, by the processing circuitry, cooling of an emission region of the side fire probe while the emissions are deactivated from exiting the side fire probe.
6. The method of claim 5, further comprising: controlling the cooling of the emission region of the side fire probe to hold the side fire probe at a temperature that is within a specified temperature range.
7. The method of claim 5, wherein delivering thermal therapy to the three-dimensional region of interest further comprises reading, by the processing circuitry, a thermocouple of the side fire probe while the emissions are deactivated from exiting the side fire probe.
8. A system for effecting thermal therapy using an in vivo side fire laser probe, comprising: a processor; anda memory having instructions stored thereon, wherein the instructions, when executed by the processor, cause the processor to: identify a three-dimensional region of interest at which to apply thermal therapy within a volume of a patient, wherein the side fire laser probe is positioned in the volume;identify, based upon one or more of a) a probe type, b) a probe emission style, and c) a depth of the three-dimensional region of interest, a pulsed energy output pattern, wherein the pulsed energy output pattern comprises an active duration and an inactive duration, wherein the inactive duration is selected to avoid tissue scorching, andthe pulsed energy output pattern is delivered at a higher power density than achievable without causing tissue scorching using a constantly active energy output; andcause application of the pulsed energy output pattern to the three-dimensional region of interest along a first trajectory, wherein causing application of the pulsed energy output pattern comprises a) activating probe emission for the active duration at a power output,b) deactivating probe emission for the inactive duration,c) repeating steps a) and b) while monitoring feedback data until identifying, based upon the feedback data, evidence of potential damage to tissue proximate an emission region of the probe;d) responsive to identifying the evidence of potential damage, adjusting at least one of a) a period of the inactive duration and b) a period of the active duration to avoid overheating the tissue closest to the emission region, ande) continuing to repeat steps a) and b) while monitoring further feedback data until identifying, based upon the further feedback data, conclusion of the thermal therapy;wherein the feedback data and further feedback data comprise at least one of temperature-sensitive data and imaging data, andthe feedback data and further feedback data are provided by at least one of a magnetic resonance (MR) imaging system and a thermometry imaging system.
9. The system of claim 8, wherein the active duration is at least 1 second.
10. The system of claim 8, wherein identifying the three-dimensional region of interest comprises identifying the three-dimensional region of interest within Digital Imaging in Communications and Medicine (DICOM) format data.
11. The system of claim 8, wherein the instructions, when executed, further cause the processor to capture, via magnetic resonance (MR) imaging equipment, magnetic resonance (MR) image data of the patient, wherein identifying the three-dimensional region of interest comprises identifying the three-dimensional region of interest within the MR image data.
12. The system of claim 8, wherein causing application of the pulsed energy output pattern further comprises, responsive to identifying the evidence of potential damage, adjusting the power output.
13. The system of claim 8, wherein: monitoring feedback data comprises determining a temperature at tissue closest to the emission region of the side fire probe; andadjusting the period of the inactive duration comprises lengthening the period of the inactive duration responsive to the temperature at the tissue to avoid overheating the tissue closest to the emission region of the side fire probe.
14. A non-transitory computer readable medium having instructions stored thereon, wherein the instructions, when executed by a processor, cause the processor to: identify a three-dimensional region of interest at which to apply thermal therapy within a volume of a patient using a laser probe, wherein the laser probe is positioned in the volume;identify a pulsed energy output pattern, wherein the pulsed energy output pattern comprises an active duration, a target energy level, and an inactive duration, wherein the inactive duration is selected to avoid tissue scorching, andthe pulsed energy output pattern is delivered at a higher power density than achievable without causing tissue scorching using a constantly active energy output; andcause application of the pulsed energy output pattern to the three-dimensional region of interest by the probe in an initial trajectory, wherein causing application of the pulsed energy output pattern comprises a) activating probe emission for the active duration at the target energy level,b) deactivating probe emission for the inactive duration, andc) repeating steps a) and b) while monitoring feedback data, until identifying, within the feedback data, evidence comprising at least one of i) evidence of potential damage to tissue proximate to an emission region of the probe, and ii) evidence of a mismatch between a target depth of treatment and an actual depth of treatment, andd) responsive to identifying the evidence, adjusting at least one of the inactive duration and the active duration.
15. The computer readable medium of claim 14, wherein causing application of the pulsed energy output pattern further comprises repeating steps a) and b) while monitoring feedback data until determining completion of thermal therapy, wherein determining completion comprises at least one of i) identifying the three-dimensional region of interest has reached a target temperature, and ii) identifying a thermal dose that is based on a temperature history of the three-dimensional region of interest over a specified time period.
16. The computer readable medium of claim 14, wherein: monitoring the feedback data comprises applying thermographic analysis of MR images; andidentifying the three-dimensional region of interest has reached the target temperature comprises indicating cellular damage within the three-dimensional region of interest.
17. The computer readable medium of claim 14, wherein causing application of the pulsed energy output pattern further comprises, during the inactive duration, activating cooling of the emission region of the probe.
18. The computer readable medium of claim 17, wherein activating probe emission comprises transmitting one or more control signals to an energy emission source to activate energy emission of a side fire probe that directs energy via uncoated fiber tip; and activating cooling of the emission region of the probe comprises transmitting one or more control signals to a cooling fluid source to select one of a cooling fluid pressure and a cooling fluid flow rate to circulate gas around the emission region of the probe.
19. The computer readable medium of claim 16, wherein identifying the three-dimensional region of interest has reached the target temperature comprises identifying indication of cell death.
20. The computer readable medium of claim 16, wherein identifying the three-dimensional region of interest has reached the target temperature comprises identifying indication of reversible cell damage.

RELATED APPLICATIONS

The present application is related to and claims the priority of U.S. Provisional Patent Application 61/955,121 entitled “Image-Guided Therapy of a Tissue” and filed Mar. 18, 2014. The present disclosure is also related to U.S. Provisional Patent Application 61/955,124 entitled “Image-Guided Therapy of a Tissue” and filed Mar. 18, 2014. The contents of each of the above listed applications are hereby incorporated by reference in their entireties.

US Referenced Citations (622)

Number	Name	Date	Kind
3021842	Flood	Feb 1962	A
3139990	Jelatis et al.	Jul 1964	A
4111209	Wolvek et al.	Sep 1978	A
4233979	Naser	Nov 1980	A
4360028	Barbier et al.	Nov 1982	A
4378016	Loeb	Mar 1983	A
4402694	Ash et al.	Sep 1983	A
4568559	Nuwayser et al.	Feb 1986	A
4609174	Nakatani	Sep 1986	A
4622953	Gordon	Nov 1986	A
4623588	Nuwayser et al.	Nov 1986	A
4646752	Swann et al.	Mar 1987	A
4671254	Fair	Jun 1987	A
4733660	Itzkan	Mar 1988	A
4733929	Brown	Mar 1988	A
4832024	Boussignac et al.	May 1989	A
4914608	LeBihan et al.	Apr 1990	A
4986628	Lozhenko et al.	Jan 1991	A
5059415	Neuwelt	Oct 1991	A
5078140	Kwoh	Jan 1992	A
5085219	Ortendahl et al.	Feb 1992	A
5092891	Kummer et al.	Mar 1992	A
5102410	Dressel	Apr 1992	A
5116344	Sundqvist	May 1992	A
5154723	Kubota et al.	Oct 1992	A
5192278	Hayes et al.	Mar 1993	A
5196005	Doiron et al.	Mar 1993	A
5201742	Hasson	Apr 1993	A
5207669	Baker et al.	May 1993	A
5207681	Ghadjar et al.	May 1993	A
5217441	Shichman	Jun 1993	A
5222953	Dowlatshahi	Jun 1993	A
5230338	Allen et al.	Jul 1993	A
5242438	Saadatmanesh et al.	Sep 1993	A
5246436	Rowe	Sep 1993	A
5247935	Cline et al.	Sep 1993	A
5263956	Nobles	Nov 1993	A
5269777	Doiron et al.	Dec 1993	A
5275165	Ettinger et al.	Jan 1994	A
5281213	Milder et al.	Jan 1994	A
5284144	Delannoy	Feb 1994	A
5291890	Cline et al.	Mar 1994	A
5292320	Brown et al.	Mar 1994	A
5307144	Hiroshi et al.	Apr 1994	A
5307812	Hardy et al.	May 1994	A
5312351	Gerrone	May 1994	A
5320617	Leach	Jun 1994	A
5323779	Hardy et al.	Jun 1994	A
5327884	Hardy et al.	Jul 1994	A
5343543	Noval, Jr. et al.	Aug 1994	A
5344418	Ghaffari	Sep 1994	A
5344419	Spears	Sep 1994	A
5348048	Schirado	Sep 1994	A
5354293	Beyer et al.	Oct 1994	A
5354294	Chou	Oct 1994	A
5366456	Rink et al.	Nov 1994	A
5368031	Cline et al.	Nov 1994	A
5368032	Cline et al.	Nov 1994	A
5370649	Gardetto et al.	Dec 1994	A
5374266	Kataoka et al.	Dec 1994	A
5387220	Pisharodi	Feb 1995	A
5388580	Sullivan et al.	Feb 1995	A
5409493	Greenberg	Apr 1995	A
5433717	Rubinsky et al.	Jul 1995	A
5443068	Cline et al.	Aug 1995	A
5445166	Taylor	Aug 1995	A
5454794	Narciso et al.	Oct 1995	A
5454807	Lennox	Oct 1995	A
5454897	Vaniglia	Oct 1995	A
5469353	Pinsky et al.	Nov 1995	A
5474564	Clayman et al.	Dec 1995	A
5476461	Cho et al.	Dec 1995	A
5490840	Uzgiris et al.	Feb 1996	A
5492122	Button et al.	Feb 1996	A
5496308	Brown et al.	Mar 1996	A
5499313	Kleinerman	Mar 1996	A
5509917	Cecchetti et al.	Apr 1996	A
5526814	Cline et al.	Jun 1996	A
5530780	Ohsawa	Jun 1996	A
5534000	Bruce	Jul 1996	A
5537499	Brekke	Jul 1996	A
5553618	Suzuki et al.	Sep 1996	A
5562688	Riza	Oct 1996	A
5568503	Omori	Oct 1996	A
5571099	Purcell, Jr. et al.	Nov 1996	A
5590653	Aida et al.	Jan 1997	A
5620479	Diederich	Apr 1997	A
5632767	Sinofsky	May 1997	A
5636259	Khutoryansky et al.	Jun 1997	A
5638819	Manwaring et al.	Jun 1997	A
5643179	Fujimoto	Jul 1997	A
5647361	Damadian	Jul 1997	A
5655084	Pinsky et al.	Aug 1997	A
5657760	Ying et al.	Aug 1997	A
5663646	Kuth et al.	Sep 1997	A
5671353	Tian et al.	Sep 1997	A
5672171	Andrus et al.	Sep 1997	A
5672172	Zupkas	Sep 1997	A
5695501	Carol et al.	Dec 1997	A
5711300	Schneider et al.	Jan 1998	A
5715823	Wood et al.	Feb 1998	A
5716369	Riza	Feb 1998	A
5719975	Wolfson et al.	Feb 1998	A
5728106	Misko et al.	Mar 1998	A
5733277	Pallarito	Mar 1998	A
5735846	Panescu et al.	Apr 1998	A
5749362	Funda et al.	May 1998	A
5749549	Ashjaee	May 1998	A
5752962	D'Urso	May 1998	A
5762066	Law et al.	Jun 1998	A
5769790	Watkins et al.	Jun 1998	A
5772657	Hmelar et al.	Jun 1998	A
5785704	Bille	Jul 1998	A
5792110	Cunningham	Aug 1998	A
5807383	Kolesa et al.	Sep 1998	A
5814008	Chen et al.	Sep 1998	A
5817036	Anthony et al.	Oct 1998	A
5823941	Shaunnessey	Oct 1998	A
5824005	Motamedi et al.	Oct 1998	A
5830209	Savage et al.	Nov 1998	A
5848967	Cosman	Dec 1998	A
5855582	Gildenberg	Jan 1999	A
5855583	Wang et al.	Jan 1999	A
5861020	Schwarzmaier	Jan 1999	A
5873845	Cline et al.	Feb 1999	A
5874955	Rogowitz et al.	Feb 1999	A
5876342	Chen et al.	Mar 1999	A
5890897	Kruger et al.	Apr 1999	A
5891100	Fleckenstein	Apr 1999	A
5891157	Day et al.	Apr 1999	A
5897495	Aida et al.	Apr 1999	A
5916161	Ishihara et al.	Jun 1999	A
5928145	Ocali et al.	Jul 1999	A
5944663	Kuth et al.	Aug 1999	A
5945827	Gronauer et al.	Aug 1999	A
5947958	Woodard et al.	Sep 1999	A
5949929	Hamm	Sep 1999	A
5959246	Gretz	Sep 1999	A
5961466	Anbar	Oct 1999	A
5978541	Doiron et al.	Nov 1999	A
5989246	Kaufmann et al.	Nov 1999	A
5993463	Truwit	Nov 1999	A
6004315	Dumont	Dec 1999	A
6006126	Cosman	Dec 1999	A
6019724	Gronningsaeter et al.	Feb 2000	A
6022309	Celliers et al.	Feb 2000	A
6039728	Berlien et al.	Mar 2000	A
6047216	Carl et al.	Apr 2000	A
6050943	Slayton et al.	Apr 2000	A
6053912	Panescu et al.	Apr 2000	A
6058323	Lemelson	May 2000	A
6067371	Gouge et al.	May 2000	A
6071288	Carol et al.	Jun 2000	A
6081533	Laubach et al.	Jun 2000	A
6086532	Panescu et al.	Jul 2000	A
6106516	Massengill	Aug 2000	A
6117143	Hynes et al.	Sep 2000	A
6123719	Masychev	Sep 2000	A
6128522	Acker et al.	Oct 2000	A
6129670	Burdette	Oct 2000	A
6131480	Yoneyama	Oct 2000	A
6132437	Omurtag et al.	Oct 2000	A
6133306	Beal	Oct 2000	A
6143018	Beuthan et al.	Nov 2000	A
6148225	Kestler et al.	Nov 2000	A
6151404	Pieper	Nov 2000	A
6152933	Werp et al.	Nov 2000	A
6159150	Yale et al.	Dec 2000	A
6162052	Kokubu	Dec 2000	A
6164843	Battocchio	Dec 2000	A
6167295	Cosman	Dec 2000	A
6179831	Bliweis	Jan 2001	B1
6195579	Carroll et al.	Feb 2001	B1
6206873	Paolini et al.	Mar 2001	B1
6206885	Ghahremani et al.	Mar 2001	B1
6206890	Truwit	Mar 2001	B1
6226680	Boucher et al.	May 2001	B1
6241725	Cosman	Jun 2001	B1
6246200	Blumenkranz et al.	Jun 2001	B1
6246896	Dumoulin et al.	Jun 2001	B1
6246912	Sluijter et al.	Jun 2001	B1
6254043	Schwärzler	Jul 2001	B1
6263229	Atalar et al.	Jul 2001	B1
6267769	Truwit	Jul 2001	B1
6267770	Truwit	Jul 2001	B1
6280384	Loeffler	Aug 2001	B1
6283958	Vogl et al.	Sep 2001	B1
6283988	Laufer et al.	Sep 2001	B1
6286795	Johnson	Sep 2001	B1
6293282	Lemelson	Sep 2001	B1
6320928	Vaillant et al.	Nov 2001	B1
6321266	Yokomizo et al.	Nov 2001	B1
6332891	Himes	Dec 2001	B1
6334847	Fenster et al.	Jan 2002	B1
6353445	Babula et al.	Mar 2002	B1
6355028	Castaneda et al.	Mar 2002	B2
6368329	Truwit	Apr 2002	B1
6368330	Hynes et al.	Apr 2002	B1
6397098	Uber, III et al.	May 2002	B1
6398777	Navarro	Jun 2002	B1
6398778	Gu et al.	Jun 2002	B1
6409722	Hoey et al.	Jun 2002	B1
6413253	Koop	Jul 2002	B1
6413263	Lobdill et al.	Jul 2002	B1
6416520	Kynast et al.	Jul 2002	B1
6418337	Torchia	Jul 2002	B1
6419648	Vitek et al.	Jul 2002	B1
6423057	He et al.	Jul 2002	B1
6423077	Carol et al.	Jul 2002	B2
6425867	Vaezy et al.	Jul 2002	B1
6440127	McGovern et al.	Aug 2002	B2
6447505	McGovern et al.	Sep 2002	B2
6451007	Koop et al.	Sep 2002	B1
6451015	Rittman, III et al.	Sep 2002	B1
6454774	Fleckenstein	Sep 2002	B1
6461314	Pant et al.	Oct 2002	B1
6464690	Castaneda et al.	Oct 2002	B1
6464691	Castaneda et al.	Oct 2002	B1
6464694	Massengill	Oct 2002	B1
6468238	Hawkins et al.	Oct 2002	B1
6488697	Ariura et al.	Dec 2002	B1
6491699	Henderson et al.	Dec 2002	B1
6501978	Wagshul et al.	Dec 2002	B2
6506154	Ezion et al.	Jan 2003	B1
6506171	Vitek et al.	Jan 2003	B1
6507747	Gowda et al.	Jan 2003	B1
6510241	Vaillant et al.	Jan 2003	B1
6522142	Freundlich	Feb 2003	B1
6522913	Swanson et al.	Feb 2003	B2
6529765	Franck et al.	Mar 2003	B1
6542767	McNichols et al.	Apr 2003	B1
6543272	Vitek	Apr 2003	B1
6544248	Bass	Apr 2003	B1
6544257	Nagase et al.	Apr 2003	B2
6549800	Atalar et al.	Apr 2003	B1
6551274	Heiner	Apr 2003	B2
6554826	Deardorff	Apr 2003	B1
6558375	Sinofsky et al.	May 2003	B1
6559644	Froundlich et al.	May 2003	B2
6577888	Chan et al.	Jun 2003	B1
6579281	Palmer et al.	Jun 2003	B2
6582381	Yehezkeli et al.	Jun 2003	B1
6582420	Castaneda et al.	Jun 2003	B2
6585665	Chapman et al.	Jul 2003	B1
6589174	Chopra et al.	Jul 2003	B1
6589233	Maki	Jul 2003	B1
6591128	Wu et al.	Jul 2003	B1
6603988	Dowlatshahi	Aug 2003	B2
6606091	Liang et al.	Aug 2003	B2
6606513	Lardo et al.	Aug 2003	B2
6612988	Maor et al.	Sep 2003	B2
6613004	Vitek et al.	Sep 2003	B1
6613005	Friedman et al.	Sep 2003	B1
6618608	Watkins et al.	Sep 2003	B1
6618620	Freundlich et al.	Sep 2003	B1
6623490	Crane et al.	Sep 2003	B1
6626854	Friedman et al.	Sep 2003	B2
6628980	Atalar et al.	Sep 2003	B2
6631499	Tsujii	Oct 2003	B1
6645162	Friedman et al.	Nov 2003	B2
6666833	Friedman et al.	Dec 2003	B1
6671535	McNichols et al.	Dec 2003	B1
6675033	Lardo et al.	Jan 2004	B1
6675037	Tsekos	Jan 2004	B1
6684097	Parel et al.	Jan 2004	B1
6695871	Maki et al.	Feb 2004	B1
6701176	Halperin et al.	Mar 2004	B1
6701181	Tang et al.	Mar 2004	B2
6705994	Vortman et al.	Mar 2004	B2
6716215	David et al.	Apr 2004	B1
6731966	Spigelman et al.	May 2004	B1
6735461	Vitek et al.	May 2004	B2
6741883	Gildenberg	May 2004	B2
6752812	Truwit	Jun 2004	B1
6755849	Gowda et al.	Jun 2004	B1
6770031	Hynynen et al.	Aug 2004	B2
6773408	Acker et al.	Aug 2004	B1
6782288	Truwit et al.	Aug 2004	B2
6790180	Vitek	Sep 2004	B2
6801643	Pieper	Oct 2004	B2
6823216	Salomir et al.	Nov 2004	B1
6825838	Smith et al.	Nov 2004	B2
6843793	Brock et al.	Jan 2005	B2
6845193	Loeb et al.	Jan 2005	B2
6893447	Dominguez et al.	May 2005	B2
6898454	Atalar et al.	May 2005	B2
6902569	Parmer et al.	Jun 2005	B2
6904307	Karmarkar et al.	Jun 2005	B2
6986764	Davenport et al.	Jan 2006	B2
7033367	Ghahremani et al.	Apr 2006	B2
7072704	Bucholz	Jul 2006	B2
7074233	Gowda et al.	Jul 2006	B1
7097641	Arless et al.	Aug 2006	B1
7123255	Trousett et al.	Oct 2006	B2
7128711	Medan et al.	Oct 2006	B2
7133714	Karmarkar et al.	Nov 2006	B2
7163542	Ryan	Jan 2007	B2
7164940	Hareyama et al.	Jan 2007	B2
7166458	Ballerstadt et al.	Jan 2007	B2
7167741	Torchia et al.	Jan 2007	B2
7167760	Dawant et al.	Jan 2007	B2
7175596	Vitek et al.	Feb 2007	B2
7226414	Ballerstadt et al.	Jun 2007	B2
7228165	Sullivan	Jun 2007	B1
7229451	Day et al.	Jun 2007	B2
7235084	Skakoon et al.	Jun 2007	B2
7235089	McGuckin, Jr.	Jun 2007	B1
7236812	Ballerstadt et al.	Jun 2007	B1
7236816	Kumar et al.	Jun 2007	B2
7270656	Gowda et al.	Sep 2007	B2
7274847	Gowda et al.	Sep 2007	B2
7280686	Hornegger et al.	Oct 2007	B2
7292719	Arnon	Nov 2007	B2
7315167	Bottcher et al.	Jan 2008	B2
7321374	Naske	Jan 2008	B2
7344529	Torchia et al.	Mar 2008	B2
RE40279	Sluijter et al.	Apr 2008	E
7366561	Mills et al.	Apr 2008	B2
7371210	Brock et al.	May 2008	B2
7377900	Vitek et al.	May 2008	B2
7412141	Gowda et al.	Aug 2008	B2
7450985	Meloy et al.	Nov 2008	B2
7463801	Brekke et al.	Dec 2008	B2
7479139	Cytron et al.	Jan 2009	B2
7489133	Keidl et al.	Feb 2009	B1
7494489	Roh	Feb 2009	B2
7507244	Dinkler et al.	Mar 2009	B2
7519210	Hirsch et al.	Apr 2009	B2
7521930	Li et al.	Apr 2009	B2
7535794	Prus et al.	May 2009	B2
7551953	Lardo et al.	Jun 2009	B2
7561906	Atalar et al.	Jul 2009	B2
7599729	Atalar et al.	Oct 2009	B2
7602190	Piferi et al.	Oct 2009	B2
7609927	Gowda et al.	Oct 2009	B2
7611462	Vortman et al.	Nov 2009	B2
7631233	Parris et al.	Dec 2009	B2
7634119	Tsougarakis et al.	Dec 2009	B2
7652410	Prus	Jan 2010	B2
7659719	Vaughan et al.	Feb 2010	B2
7661162	Soerensen et al.	Feb 2010	B2
7699780	Vitek et al.	Apr 2010	B2
7702140	Hirsch et al.	Apr 2010	B2
7706858	Green et al.	Apr 2010	B1
7717853	Nita et al.	May 2010	B2
7736371	Schoepp	Jun 2010	B2
7778682	Kumar et al.	Aug 2010	B2
7792566	Roland et al.	Sep 2010	B2
7794469	Kao et al.	Sep 2010	B2
7801587	Webber et al.	Sep 2010	B2
7848788	Tulley et al.	Dec 2010	B2
7876939	Yankelevitz et al.	Jan 2011	B2
7925328	Urquhart et al.	Apr 2011	B2
7957783	Atalar et al.	Jun 2011	B2
8002706	Vortman et al.	Aug 2011	B2
8022705	Bogdanov et al.	Sep 2011	B2
RE42856	Karmarkar et al.	Oct 2011	E
8029471	Khan-Sahibzada et al.	Oct 2011	B1
8034569	Jackson et al.	Oct 2011	B2
8055351	Atalar et al.	Nov 2011	B2
8060182	He et al.	Nov 2011	B2
8068893	Guttman et al.	Nov 2011	B2
8088067	Vortman et al.	Jan 2012	B2
8094900	Steines et al.	Jan 2012	B2
8099150	Piferi et al.	Jan 2012	B2
8100132	Markstroem et al.	Jan 2012	B2
8108028	Karmarkar	Jan 2012	B2
8114068	Rheinwald et al.	Feb 2012	B2
8116843	Dai et al.	Feb 2012	B2
8157828	Piferi	Apr 2012	B2
8165658	Waynik et al.	Apr 2012	B2
8175677	Sayler et al.	May 2012	B2
8190237	Driemel et al.	May 2012	B2
8195272	Piferi et al.	Jun 2012	B2
8208993	Piferi et al.	Jun 2012	B2
8211095	Gowda et al.	Jul 2012	B2
8216854	Ballerstadt et al.	Jul 2012	B2
8221427	Roh	Jul 2012	B2
8224420	Mu et al.	Jul 2012	B2
8233701	Frakes et al.	Jul 2012	B2
8235901	Schmidt et al.	Aug 2012	B2
8251908	Vortman et al.	Aug 2012	B2
8267938	Murphy	Sep 2012	B2
8270698	Geiger	Sep 2012	B2
8285097	Griffin	Oct 2012	B2
8287537	Dinkler	Oct 2012	B2
8295912	Gertner	Oct 2012	B2
8298245	Li et al.	Oct 2012	B2
8314052	Jackson	Nov 2012	B2
8315689	Jenkins et al.	Nov 2012	B2
8320990	Vij	Nov 2012	B2
8340743	Jenkins et al.	Dec 2012	B2
RE43901	Freundlich et al.	Jan 2013	E
8343138	Asfora	Jan 2013	B2
8364217	Ballerstadt et al.	Jan 2013	B2
8368401	Levy et al.	Feb 2013	B2
8369930	Jenkins et al.	Feb 2013	B2
8374677	Piferi et al.	Feb 2013	B2
8380277	Atalar et al.	Feb 2013	B2
8396532	Jenkins et al.	Mar 2013	B2
8404495	Ballerstadt et al.	Mar 2013	B2
8409099	Vitek et al.	Apr 2013	B2
8414597	Kao et al.	Apr 2013	B2
8425424	Zadicario et al.	Apr 2013	B2
8433421	Atalar et al.	Apr 2013	B2
8482285	Grissom et al.	Jul 2013	B2
8520932	Cool et al.	Aug 2013	B2
8548561	Vortman et al.	Oct 2013	B2
8548569	Piferi et al.	Oct 2013	B2
8608672	Vortman et al.	Dec 2013	B2
8617073	Prus et al.	Dec 2013	B2
RE44726	Parris et al.	Jan 2014	E
RE44736	Karmarkar et al.	Jan 2014	E
8644906	Piferi et al.	Feb 2014	B2
8649842	Atalar et al.	Feb 2014	B2
8661873	Medan et al.	Mar 2014	B2
8688226	Atalar et al.	Apr 2014	B2
8737712	Geiger	May 2014	B2
20010003798	McGovern et al.	Jun 2001	A1
20020019641	Truwit	Feb 2002	A1
20020042605	Castaneda et al.	Apr 2002	A1
20020052610	Skakoon et al.	May 2002	A1
20020087148	Brock et al.	Jul 2002	A1
20020169460	Foster et al.	Nov 2002	A1
20020177843	Anderson et al.	Nov 2002	A1
20030018329	Hooven	Jan 2003	A1
20030023236	Gowda et al.	Jan 2003	A1
20030060813	Loeb et al.	Mar 2003	A1
20030171741	Ziebol et al.	Sep 2003	A1
20030187371	Vortman et al.	Oct 2003	A1
20040030227	Littrup et al.	Feb 2004	A1
20040073100	Ballerstadt et al.	Apr 2004	A1
20040075031	Crain et al.	Apr 2004	A1
20040122446	Solar	Jun 2004	A1
20040123870	Stamper et al.	Jul 2004	A1
20040133190	Hobart et al.	Jul 2004	A1
20040134884	Wei et al.	Jul 2004	A1
20040167542	Solar et al.	Aug 2004	A1
20040167543	Mazzocchi et al.	Aug 2004	A1
20040267284	Parmer et al.	Dec 2004	A1
20050065429	Zhou	Mar 2005	A1
20050070920	Solar et al.	Mar 2005	A1
20050154378	Teague et al.	Jul 2005	A1
20050240126	Foley	Oct 2005	A1
20060009749	Weckwerth et al.	Jan 2006	A1
20060089626	Vlegele et al.	Apr 2006	A1
20060122590	Bliweis et al.	Jun 2006	A1
20060122629	Skakoon	Jun 2006	A1
20060175484	Wood, III et al.	Aug 2006	A1
20060192319	Solar et al.	Aug 2006	A1
20060195119	Mazzocchi et al.	Aug 2006	A1
20060206105	Chopra et al.	Sep 2006	A1
20060212044	Bova et al.	Sep 2006	A1
20060229641	Gupta et al.	Oct 2006	A1
20060241393	Liu et al.	Oct 2006	A1
20060287647	Torchia et al.	Dec 2006	A1
20070016039	Vortman et al.	Jan 2007	A1
20070043342	Kleinberger	Feb 2007	A1
20070088416	Atalar et al.	Apr 2007	A1
20070100346	Wyss et al.	May 2007	A1
20070106305	Kao et al.	May 2007	A1
20070149977	Heavener	Jun 2007	A1
20070191867	Mazzocchi et al.	Aug 2007	A1
20070197918	Vitek et al.	Aug 2007	A1
20070208352	Henderson et al.	Sep 2007	A1
20070225562	Spivey et al.	Sep 2007	A1
20070238978	Kumar et al.	Oct 2007	A1
20070239062	Chopra et al.	Oct 2007	A1
20070249934	Aksit	Oct 2007	A1
20070250077	Skakoon et al.	Oct 2007	A1
20070270717	Tang et al.	Nov 2007	A1
20070282404	Cottrell et al.	Dec 2007	A1
20080002927	Furnish	Jan 2008	A1
20080027463	Labadie et al.	Jan 2008	A1
20080033278	Assif	Feb 2008	A1
20080033292	Shafran	Feb 2008	A1
20080046122	Manzo	Feb 2008	A1
20080077159	Madhani et al.	Mar 2008	A1
20080097187	Gielen et al.	Apr 2008	A1
20080114340	Fox et al.	May 2008	A1
20080123921	Gielen et al.	May 2008	A1
20080123922	Gielen et al.	May 2008	A1
20080195085	Loeb	Aug 2008	A1
20080208034	Yang et al.	Aug 2008	A1
20080242978	Simon et al.	Oct 2008	A1
20080243142	Gildenberg	Oct 2008	A1
20080243218	Bottomley et al.	Oct 2008	A1
20080255583	Gielen et al.	Oct 2008	A1
20080262584	Bottomley et al.	Oct 2008	A1
20080269588	Csavoy et al.	Oct 2008	A1
20080269602	Csavoy et al.	Oct 2008	A1
20080287917	Cunningham	Nov 2008	A1
20080306375	Sayler et al.	Dec 2008	A1
20090012509	Csavoy et al.	Jan 2009	A1
20090018446	Medan et al.	Jan 2009	A1
20090048588	Peng et al.	Feb 2009	A1
20090048606	Tipirneni et al.	Feb 2009	A1
20090082783	Piferi	Mar 2009	A1
20090088623	Vortman et al.	Apr 2009	A1
20090099045	Jackson et al.	Apr 2009	A1
20090112082	Piferi et al.	Apr 2009	A1
20090118610	Karmarkar et al.	May 2009	A1
20090124398	Thompson	May 2009	A1
20090131783	Jenkins et al.	May 2009	A1
20090148493	Ballerstadt et al.	Jun 2009	A1
20090163836	Sliwa	Jun 2009	A1
20090192487	Broaddus et al.	Jul 2009	A1
20090198309	Gowda et al.	Aug 2009	A1
20090204111	Bissig et al.	Aug 2009	A1
20090234368	Gore	Sep 2009	A1
20090240242	Neuberger	Sep 2009	A1
20090266760	Jackson et al.	Oct 2009	A1
20090275130	Navran et al.	Nov 2009	A1
20090287199	Hanley et al.	Nov 2009	A1
20090308400	Wilson et al.	Dec 2009	A1
20090326525	Hixon et al.	Dec 2009	A1
20100016930	Gowda et al.	Jan 2010	A1
20100022951	Ferrera et al.	Jan 2010	A1
20100030076	Vortman et al.	Feb 2010	A1
20100041938	Stoianovici et al.	Feb 2010	A1
20100042112	Qureshi et al.	Feb 2010	A1
20100079580	Waring, IV	Apr 2010	A1
20100082035	Keefer	Apr 2010	A1
20100087336	Jackson et al.	Apr 2010	A1
20100146713	Medan et al.	Jun 2010	A1
20100179425	Zadicario	Jul 2010	A1
20100185087	Nields	Jul 2010	A1
20100198052	Jenkins et al.	Aug 2010	A1
20100210976	Darlington	Aug 2010	A1
20100241036	Vortman et al.	Sep 2010	A1
20100305580	Henderson et al.	Dec 2010	A1
20100312094	Guttman et al.	Dec 2010	A1
20100312095	Jenkins et al.	Dec 2010	A1
20100312096	Guttman et al.	Dec 2010	A1
20100318002	Prus et al.	Dec 2010	A1
20110009734	Foley et al.	Jan 2011	A1
20110009828	Prechtel et al.	Jan 2011	A1
20110034800	Vitek et al.	Feb 2011	A1
20110040172	Carpentier et al.	Feb 2011	A1
20110046472	Schmidt et al.	Feb 2011	A1
20110046475	Assif et al.	Feb 2011	A1
20110066032	Vitek et al.	Mar 2011	A1
20110118715	Zerfas	May 2011	A1
20110137147	Skliar et al.	Jun 2011	A1
20110141759	Smith	Jun 2011	A1
20110152730	Kohler et al.	Jun 2011	A1
20110166447	Windolf et al.	Jul 2011	A1
20110175615	Grissom et al.	Jul 2011	A1
20110190787	Sahni et al.	Aug 2011	A1
20110217665	Walsh et al.	Sep 2011	A1
20110224576	Jackson et al.	Sep 2011	A1
20110226260	Eder et al.	Sep 2011	A1
20110230753	Mahon et al.	Sep 2011	A1
20110237930	Donaldson et al.	Sep 2011	A1
20110238139	Gowda et al.	Sep 2011	A1
20110251528	Canney et al.	Oct 2011	A1
20110260728	Biber et al.	Oct 2011	A1
20110267059	Shvartsberg et al.	Nov 2011	A1
20110270075	Vitek et al.	Nov 2011	A1
20110270136	Vitek et al.	Nov 2011	A1
20110270366	Mahon et al.	Nov 2011	A1
20110295161	Chopra et al.	Dec 2011	A1
20110301450	Hue et al.	Dec 2011	A1
20110306054	Jackson et al.	Dec 2011	A1
20110319747	Schmidt et al.	Dec 2011	A1
20110319748	Bronskill et al.	Dec 2011	A1
20110319910	Roelle et al.	Dec 2011	A1
20120015359	Jackson et al.	Jan 2012	A1
20120029396	Vortman et al.	Feb 2012	A1
20120053573	Alksnis	Mar 2012	A1
20120059243	Vortman et al.	Mar 2012	A1
20120059335	Bobo, Sr.	Mar 2012	A1
20120070058	Raju	Mar 2012	A1
20120071746	Vortman et al.	Mar 2012	A1
20120095364	Bobo, Sr.	Apr 2012	A1
20120101412	Vortman et al.	Apr 2012	A1
20120108459	Jackson et al.	May 2012	A1
20120121533	Jackson	May 2012	A1
20120165225	Stepanov et al.	Jun 2012	A1
20120191020	Vitek et al.	Jul 2012	A1
20120197112	McNichols	Aug 2012	A1
20120232375	Zebaze et al.	Sep 2012	A1
20120245573	Gowda et al.	Sep 2012	A1
20130006095	Jenkins et al.	Jan 2013	A1
20130018430	Murphy	Jan 2013	A1
20130030283	Vortman	Jan 2013	A1
20130030408	Piferi et al.	Jan 2013	A1
20130034915	Ballerstadt et al.	Feb 2013	A1
20130035582	Radulescu et al.	Feb 2013	A1
20130041356	Smith et al.	Feb 2013	A1
20130053678	Vitek et al.	Feb 2013	A1
20130053867	Gowda et al.	Feb 2013	A1
20130060253	Couture et al.	Mar 2013	A1
20130085342	Stefanchik et al.	Apr 2013	A1
20130096597	Anand	Apr 2013	A1
20130102883	Piferi et al.	Apr 2013	A1
20130116543	Jenkins et al.	May 2013	A1
20130119984	Levy et al.	May 2013	A1
20130123598	Jenkins et al.	May 2013	A1
20130131496	Jenkins et al.	May 2013	A1
20130150704	Vitek et al.	Jun 2013	A1
20130150756	Vitek et al.	Jun 2013	A1
20130157871	Jackson	Jun 2013	A1
20130158577	Mahon et al.	Jun 2013	A1
20130163841	Geiger	Jun 2013	A1
20130184563	Driemel et al.	Jul 2013	A1
20130190607	Biber et al.	Jul 2013	A1
20130217950	Partanen et al.	Aug 2013	A1
20130245243	Jackson	Sep 2013	A1
20130245741	Atalar et al.	Sep 2013	A1
20130274778	Mercier et al.	Oct 2013	A1
20130296743	Lee	Nov 2013	A1
20130325012	Piferi et al.	Dec 2013	A1
20140024909	Vij et al.	Jan 2014	A1
20140024925	Piferi	Jan 2014	A1
20140024927	Piferi	Jan 2014	A1
20140034377	Vij	Feb 2014	A1
20140046167	Vij et al.	Feb 2014	A1
20140046343	Okazaki et al.	Feb 2014	A1
20140066750	Piferi et al.	Mar 2014	A1
20140066953	Keating et al.	Mar 2014	A1
20140112095	Medan et al.	Apr 2014	A1

Foreign Referenced Citations (199)

Number	Date	Country
2348867	May 2000	CA
2370222	Oct 2000	CA
2398967	Aug 2001	CA
2403822	Oct 2001	CA
2404352	Oct 2001	CA
2482291	Oct 2002	CA
2587691	May 2006	CA
2606824	Nov 2006	CA
2623453	Apr 2007	CA
2679498	Sep 2008	CA
2681367	Sep 2008	CA
2695494	Dec 2008	CA
2700523	Apr 2009	CA
2700529	Apr 2009	CA
2700531	Apr 2009	CA
2700577	Apr 2009	CA
2700607	Apr 2009	CA
2704739	Apr 2009	CA
2252431	Jul 2009	CA
2648973	Jul 2009	CA
2715015	Sep 2009	CA
2748053	Apr 2010	CA
2753397	Sep 2010	CA
2372001	Oct 2010	CA
2764677	Dec 2010	CA
1317641	May 2011	CA
2487140	Sep 2011	CA
2800238	Sep 2011	CA
2482202	Jul 2012	CA
2849106	Apr 2013	CA
2575313	Jul 2013	CA
2548226	Jan 2014	CA
2620289	Jun 2004	CN
2748071	Dec 2005	CN
101040772	Sep 2007	CN
101194853	Jun 2008	CN
26 21 909	Dec 1977	DE
0 610 991	Aug 1994	EP
0 614 651	Sep 1994	EP
0 755 697	Jan 1997	EP
1 046 377	Oct 2000	EP
0 844 581	Jul 2007	EP
1 829 764	Sep 2007	EP
1 455 672	May 2008	EP
1 985 330	Oct 2008	EP
54-88120	Jul 1979	JP
59-42165	Mar 1984	JP
60-154698	Aug 1985	JP
7-308393	Nov 1995	JP
7-328028	Dec 1995	JP
9-038220	Feb 1997	JP
10-155805	Jun 1998	JP
10-258066	Sep 1998	JP
11-253562	Sep 1999	JP
2000-000319	Jan 2000	JP
2000-126316	May 2000	JP
2002-543865	Dec 2002	JP
WO 9005494	May 1990	WO
WO 9210142	Jun 1992	WO
WO 9320769	Oct 1993	WO
WO 9404220	Mar 1994	WO
WO 9423308	Oct 1994	WO
WO 9529737	Nov 1995	WO
WO 9740396	Oct 1997	WO
WO 9823214	Jun 1998	WO
WO 9851229	Nov 1998	WO
WO 9852465	Nov 1998	WO
WO 9951156	Oct 1999	WO
WO 0023000	Apr 2000	WO
WO 0028895	May 2000	WO
WO 0032102	Jun 2000	WO
WO 0062672	Oct 2000	WO
WO 0064003	Oct 2000	WO
WO 0067640	Nov 2000	WO
WO 0106925	Feb 2001	WO
WO 0125810	Apr 2001	WO
WO 0135825	May 2001	WO
WO 0140819	Jun 2001	WO
WO 0156469	Aug 2001	WO
WO 0165490	Sep 2001	WO
WO 0173461	Oct 2001	WO
WO 0174241	Oct 2001	WO
WO 0176498	Oct 2001	WO
WO 0180708	Nov 2001	WO
WO 0180709	Nov 2001	WO
WO 0182806	Nov 2001	WO
WO 0200093	Jan 2002	WO
WO 0200298	Jan 2002	WO
WO 0209812	Feb 2002	WO
WO 0224075	Mar 2002	WO
WO 0224094	Mar 2002	WO
WO 0243804	Jun 2002	WO
WO 0243805	Jun 2002	WO
WO 0244753	Jun 2002	WO
WO 0245073	Jun 2002	WO
WO 02051501	Jul 2002	WO
WO 02058791	Aug 2002	WO
WO 02083016	Oct 2002	WO
WO 02084316	Oct 2002	WO
WO 02085216	Oct 2002	WO
WO 02097466	Dec 2002	WO
WO 02103380	Dec 2002	WO
WO 03011160	Feb 2003	WO
WO 03017843	Mar 2003	WO
WO 03042707	May 2003	WO
WO 03048702	Jun 2003	WO
WO 03052444	Jun 2003	WO
WO 03094759	Nov 2003	WO
WO 03097162	Nov 2003	WO
WO 03102614	Dec 2003	WO
WO 2004056421	Jul 2004	WO
WO 2004075722	Sep 2004	WO
WO 2004103472	Dec 2004	WO
WO 2004105624	Dec 2004	WO
WO 2005046451	May 2005	WO
WO 2005046753	May 2005	WO
WO 2006014966	Feb 2006	WO
WO 2006018686	Feb 2006	WO
WO 2006021851	Mar 2006	WO
WO 2006055554	May 2006	WO
WO 2006119492	Nov 2006	WO
WO 2006136912	Dec 2006	WO
WO 2007047966	Apr 2007	WO
WO 2007056458	May 2007	WO
WO 2007060474	May 2007	WO
WO 2007064937	Jun 2007	WO
WO 2007085892	Aug 2007	WO
WO 2007129166	Nov 2007	WO
WO 2008015520	Feb 2008	WO
WO 2008015521	Feb 2008	WO
WO 2008015522	Feb 2008	WO
WO 2008015523	Feb 2008	WO
WO 2008070685	Jun 2008	WO
WO 2008109864	Sep 2008	WO
WO 2008115383	Sep 2008	WO
WO 2008115426	Sep 2008	WO
WO 2008153975	Dec 2008	WO
WO 2009007847	Jan 2009	WO
WO 2009042130	Apr 2009	WO
WO 2009042131	Apr 2009	WO
WO 2009042135	Apr 2009	WO
WO 2009042136	Apr 2009	WO
WO 2009042152	Apr 2009	WO
WO 2009042155	Apr 2009	WO
WO 2009042160	Apr 2009	WO
WO 2009044276	Apr 2009	WO
WO 2009067205	May 2009	WO
WO 2009117069	Sep 2009	WO
WO 2009124301	Oct 2009	WO
WO 2009135198	Nov 2009	WO
WO 2010030373	Mar 2010	WO
WO 2010034099	Apr 2010	WO
WO 2010058292	May 2010	WO
WO 2010058293	May 2010	WO
WO 2010082135	Jul 2010	WO
WO 2010087961	Aug 2010	WO
WO 2010110929	Sep 2010	WO
WO 2010119340	Oct 2010	WO
WO 2010141102	Dec 2010	WO
WO 2010143072	Dec 2010	WO
WO 2010144402	Dec 2010	WO
WO 2010144405	Dec 2010	WO
WO 2010144419	Dec 2010	WO
WO 2010148083	Dec 2010	WO
WO 2010148088	Dec 2010	WO
WO 2011013001	Feb 2011	WO
WO 2011015949	Feb 2011	WO
WO 2011021106	Feb 2011	WO
WO 2011024074	Mar 2011	WO
WO 2011028505	Mar 2011	WO
WO 2011045669	Apr 2011	WO
WO 2011058437	May 2011	WO
WO 2011087495	Jul 2011	WO
WO 2011090990	Jul 2011	WO
WO 2011112249	Sep 2011	WO
WO 2011112251	Sep 2011	WO
WO 2011115664	Sep 2011	WO
WO 2011130107	Oct 2011	WO
WO 2011135455	Nov 2011	WO
WO 2011135458	Nov 2011	WO
WO 2012014074	Feb 2012	WO
WO 2012038826	Mar 2012	WO
WO 2012052847	Apr 2012	WO
WO 2012112829	Aug 2012	WO
WO 2012116265	Aug 2012	WO
WO 2012147614	Nov 2012	WO
WO 2012154961	Nov 2012	WO
WO 2013028811	Feb 2013	WO
WO 2013030671	Mar 2013	WO
WO 2013049108	Apr 2013	WO
WO2013063027	May 2013	WO
WO 2013117991	Aug 2013	WO
WO 2013117992	Aug 2013	WO
WO 2013140284	Sep 2013	WO
WO 2013181008	Dec 2013	WO
WO 2013182977	Dec 2013	WO
WO 2014003855	Jan 2014	WO
WO 2014014585	Jan 2014	WO
WO 2014039481	Mar 2014	WO

Non-Patent Literature Citations (65)

Entry
Simanovskii et al, Cellular tolerance to pulsed heating, SPIE Proceedings, Laser-Tissue Interactions XVI, vol. 5695, BIOS 2005, p. 1-6.
Staehler et al, Endoscopic application of the ND: YAG laser in Urology; Theory, Results, Dosimetry, Urol. Res. 9, 1981, p. 45-51.
U.S. Appl. No. 14/661,153, filed Mar. 18, 2015, Andrews, et al.
U.S. Appl. No. 14/661,170, filed Mar. 18, 2015, Andrews, et al.
U.S. Appl. No. 14/661,310, filed Mar. 18, 2015, Andrews, et al.
International Preliminary Report on Patentability mailed Feb. 15, 2011, in PCT/CA2009/01137, 8 pages.
International Preliminary Report on Patentability mailed Feb. 15, 2011, in PCT/CA2009/001138, 5 pages.
Office Action mailed Oct. 25, 2011, in Brazilian Patent Application No. PI-0214951-6 (English translation).
Office Action mailed May 28, 2013, in Brazilian Patent Application No. PI-0214951-6 (English translation).
Office Action mailed Nov. 1, 2012, in Japanese Patent Application No. 2011-522361 (with English-language translation).
Combined Chinese OA and Search Report mailed Mar. 13, 2013, in Chinese Patent Application No. 200980131609.X.
Kahn et al., “MRI-Guided Laser-Induced Interstitial Thermotherapy of Cerebral Neoplasms,” Journal of Computer Assisted Tomography, vol. 18, No. 4, pp. 519-532, Jul./Aug. 1994, Raven Press; Ltd., New York, NY.
Kahn et al., “In Vivo MRI Thermometry Using a Phase-Sensitive Sequence: Preliminary Experience During MRI-Guided Laser-Induced Interstitial Thermotherapy of Brain Tumors,” Journal of Magnetic Resonance Imaging, vol. 8, No. 1, pp. 160-164, Williams & Wilkins, 1998, Baltimore, MD.
Vogl et al., “Internally Cooled Power Laser for MR-guided Interstitial Laser-induced Thermotherapy of Liver Lesions: Initial Clinical Results”, in Radiology, 1998, 209: pp. 381-385.
McNichols et al., “MR Thermometry-Based Feedback Control of Laser Interstitial Thermal Therapy at 980 nm,” Lasers in Surgery and Medicine, 2004, 34: 48-55, Wiley-Liss, Inc.
Schwarzmaier et al., “MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: Preliminary results in 16 patients,” European Journal of Radiology, vol. 59, Issue 2, pp. 208-215, Aug. 2006.
Office Action mailed Oct. 8, 2012, in Chinese Patent Application No. 200980131600.9 (with English-language translation).
Office Action mailed Jul. 17, 2013, in Japanese Patent Application No. 2011-522361 (with English-language translation).
Office Action mailed Jul. 29, 2013, in Japanese Patent Application No. 2011-522360 (with English-language translation).
Jerome Shaunnessey, Petition for General Supervisory Review by the Director under 37 CFR 1.181, Jul. 2014, 6 pages.
International Search Report issued Aug. 3, 2012 in PCT/IB2012/051716.
Office Action dated Nov. 1, 2012, in Japanese Patent Application No. 2011-522360 (with English Translation).
Supplementary European Search Report issued Oct. 18, 2013, in European Patent Application No. 09806277.1.
Castro et al. “Interstitial laaser phototherapy assisted by magnetic resonance imaging: A new technique for monitoring laser-tissue interaction” The Laryngoscope, vol. 100, Issue , pp. 541-547, May 1990 (abstract only).
Nabavi et al. “Neurosurgical procedures in a 0.5 tesla, open-configuration intraoperative MRI: planning, visualization, and navigation” Automedica, vol. 00, pp. 1-35, 2001.
T. Menovsky, et al., “Interstitial Laser Thermotherapy in Neurosurgery: A Review”, Acta Neurochir (Wien) (1996) 138:1019-1026, 8 pages.
Ferenc A. Jolesz M.D., et al., “MRI-Guided Laser-Induced Interstitial Thermotherapy: Basic Principles”, Harvard Medical School and Brigham and Women's Hospital, Department of Radiology, appears in: SPIE Institute on Laser-Induced Interstitial Thermotherapy (LITT), Jun. 22-23, 1995, 17 pages.
Thorsten Harth, et al., “Determination of Laser-Induced Temperature Distributions Using Echo-Shifted TurboFLASH”, MRM 38:238-245 (1997), 8 pages.
Lawrence P. Panych, et al., “Effects Related to Temperature Changes during MR Imaging”, JMRI, vol. 2, No. 1, Jan./Feb. 1992, pp. 69-74.
John De Poorter, “Noninvasive MRI Thermometry with the Proton Resonance Frequency Method: Study of Susceptibility Effects”, MRM 34:359-367 (1995), 9 pages.
Ron Corbett, et al., “Noninvasive Measurements of Human Brain Temperature Using Volume-Localized Proton Magnetic Resonance Spectroscopy”, Journal of Cerebral Blood Flow and Metabolism, vol. 17, No. 4, 1997, pp. 363-369.
Waldemar Wlodarczyk, et al., “Comparison of four magnetic resonance methods for mapping small temperature changes”, Phys. Med. Biol. 44, 1999, pp. 607-624.
Carpentier, et al. “Real-Time Magnetic Resonance-Guided Laser Thermal Therapy for Focal Metastatic Brain Tumors”, Operative Neurogurgery 1, vol. 63, 2008, pp. 21-39.
Canney, et al. “A Multi-element Interstitial Ultrasound Applicator for the Thermal Therapy of Brain Tumors”, Acoustical Society of America, Pt. 2, Aug. 2013, pp. 1647-1655.
Carpentier, et al. “MR-Guided Laser Induced Thermal Therapy (LITT) for Recurrent Glioblastomas”, Lasers in Surgery and Medicine, vol. 44, pp. 361-368, 2012.
Carpentier, et al. “Laser Thermal Therapy: Real-time MRI-guided and Computer-controlled Procedures for Metastatic Brain Tumors”, Lasers in Surgery and Medicine, vol. 43, pp. 943-950, 2011.
Gewiese, et al. “Magenetic Resonance Imaging-Controlled Laser-Induced Interstitial Thermotherapy”, Investigative Radiology, vol. 29, No. 3, pp. 345-351, 1994.
Ferenc A. Jolesz, MD, et al., “MR Imaging of Laser-Tissue Interactions”, Magnetic Resonance Imaging, Radiology 1988; 168, pp. 249-253.
Yoshimi Anzai, MD, et al., “Nd:YAG Interstitial Laser Phototherapy Guided by Magnetic Resonance Imaging in an Ex Vivo Model: Dosimetry of Laser-MR-Tissue Interaction”, Laryngoscope 101: Jul. 1991, pp. 755-760.
Harvey E. Cline, et al., “MR-Guided Focused Ultrasound Surgery”, Journal of Computer Assisted Tomography, Nov./Dec. 1992, vol. 16, No. 6, pp. 956-965.
Harvey E. Cline, PhD, et al., “Focused US System for MR Imaging-guided Tumor Ablation” Magnetic Resonance Imaging, Radiology 1995; Mar. 1995, vol. 194, No. 3, pp. 731-737.
Kullervo Hynynen, PhD, et al, “A Clinical, Noninvasive, MR Imaging-monitored Ultrasound Surgery Method”, Imaging & Therapeutic Technology, RadioGraphics 1996; Jan. 1996, vol. 16, No. 1, pp. 185-195.
Nobuhiko Hata, et al., “Computer-Assisted Intra-Operative Magnetic Resonance Imaging Monitoring of Interstitial Laser Therapy in the Brain: A Case Report”, Journal of Biomedical Optics, Jul. 1998, vol. 3, No. 3, pp. 304-311.
Joachim Kettenbach, MD, et al., “Monitoring and Visualization Techniques for MR-Guided Laser Ablations in an Open MR System” Journal of Magnetic Resonance Imaging, Jul./Aug. 1998, vol. 8, No. 4, pp. 933-943.
Ferenc A. Jolesz, MD, et al., “Integration of Interventional MRI with Computer-Assisted Surgery”, Journal of Magnetic Resonance Imaging, Jan. 2001;13(1), pp. 69-77.
Frederic C. Vimeux, et al., “Real-Time Control of Focused Ultrasound Heating Based on Rapid MR Thermometry”, Investigative Radiology, Mar. 1999, vol. 34(3), pp. 190-193.
J. Delannoy, et al., “Hyperthermia system combined with a magnetic resonance imaging unit”, Medical Physics, vol. 17, No. 5, Sep./Oct. 1990, pp. 855-860.
Zientara, Gary P., et al. “MRI monitoring of laser ablation using optical flow.” Journal of Magnetic Resonance Imaging 8.6 (1998): 1306-1318.
Alan R. Bleier, et al., “Real-Time Magnetic Resonance Imaging of Laser Heat Deposition in Tissue”, Magnetic Resonance in Medicine 21, 1991, pp. 132-137.
Kullervo Hynynen, et al., “Focused Ultrasound Thermal Surgery Guided and Monitored by Magnetic Resonance Imaging”, Interventional Radiology, 1997, vol. 2, Third Edition, pp. 1811-1816 (with cover pages).
Ferenc A. Jolesz, “MR-guided thermal ablation of brain tumors”, Interventional MR: Techniques and Clinical Experience, 1998, pp. 123-129 (with cover pages).
F.A. Jolesz, et al., “Image-Guided Neurosurgery with Intraoperative MRI”, Interventional Magnetic Resonance Imaging, 1998, pp. 253-260 (with cover pages).
Kullervo Hynynen, et al., “Principles of MR-Guided Focused Ultrasound”, Chapter 25, Interventional MRI, 1999, pp. 237-243 (with cover pages).
Masoud Panjehpour, PhD et al., “Nd:YAG Laser-Induced Interstitial Hyperthermia Using a Long Frosted Contact Probe”, Lasers in Surgery and Medicine 10, 1990, pp. 16-24.
S. Bosman, et al., “Effect of percutaneous interstitial thermal laser on normal liver of pigs: sonographic and histopathological correlations”, Br. J. Surg., May 1991, vol. 78, No. 5, pp. 572-575.
M. Fan, M.D., et al., “Interstitial 1.06 Nd:YAG Laser Thermotherapy for Brain Tumors Under Real-Time Monitoring of MRI: Experimental Study and Phase I Clinical Trial”, Journal of Clinical Laser Medicine & Surgery, vol. 10, No. 5, 1992, pp. 355-361.
Office Action mailed Dec. 27, 2013, in Israeli Patent Application No. 210878.
Office Action issued in Chinese Patent Application No. 200980131609.X on Jan. 10, 2014.
Office Action mailed Aug. 22, 2013, in Chinese Patent Application No. 200980131600.9 (with English-language translation).
Vogl et al. “Internally Cooled Power Laser for MR-guided Interstitial Laser-induced Thermotherapy of Liver Lesions: Initial Clinical Results,” Radiology, vol. 209, No. 2. 1998, 381-385.
International Search Report mailed Jul. 27, 2015 in PCT/US2015/021229 filed Mar. 18, 2015.
Roberts et al, “Magnetic Resonance-Guided Focused Ultrasound for Uterine Fibroids,” Semin Intervent Radiol. Dec. 2008; 25(4): 394-405.
Office Action issued Jul. 5, 2016 in Chinese Patent Application No. 201380043974.1.
U.S. Office Action issued Jun. 27, 2016 in U.S. Appl. No. 14/661,310, filed Mar. 18, 2015.
Lubowitz, “Thermal chondroplasty using the Smith & Nephew DYONICS GLIDER Articular Cartilage Probe,” https://www.smith-nephew.com/global/surgicaltechniques/sports%20med/dyonics--lider—pre-shapedprobe—tg—10600072a.pdf, Jul. 2006, pp. 1-8.

Related Publications (1)

	Number	Date	Country
	20150265366 A1	Sep 2015	US

Provisional Applications (1)

	Number	Date	Country
	61955121	Mar 2014	US

Image-guided therapy of a tissue

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Abstract